Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: A network meta-analysis

Cochrane Database of Systematic Reviews

Volumn 2014, Issue 12, 2014, Pages

  Palmer, Suetonia C ^a   Saglimbene, Valeria ^b   Mavridis, Dimitris ^c,d   Salanti, Georgia ^c   Craig, Jonathan C ^e,f   Tonelli, Marcello ^g   Wiebe, Natasha ^h   Strippoli, Giovanni F M ^b,e,f,i,j,k  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^c UNIVERSITY OF IOANNINA   (Greece)

^d UNIVERSITY OF IOANNINA   (Greece)

^e UNIVERSITY OF SYDNEY   (Australia)

^f CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^g UNIVERSITY OF CALGARY   (Canada)

^h UNIVERSITY OF ALBERTA   (Canada)

ⁱ UNIVERSITY OF BARI   (Italy)

^j Medical Scientific Office   (Sweden)

^k UNIVERSITY OF EASTERN PIEDMONT   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; RECOMBINANT ERYTHROPOIETIN; BIOSIMILAR AGENT; ERYTHROPOIETIN; MACROGOL DERIVATIVE; RECOMBINANT PROTEIN;

ANEMIA; ARTICLE; BLOOD TRANSFUSION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; END STAGE RENAL DISEASE; FATIGUE; HEART INFARCTION; HUMAN; MEDICATION THERAPY MANAGEMENT; META ANALYSIS; MORTALITY; MULTICENTER STUDY (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SYSTEMATIC REVIEW; THROMBOSIS; TREATMENT OUTCOME; ADULT; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; CHRONIC KIDNEY FAILURE; COMPLICATION; HYPERTENSION;

ADULT; ANEMIA; BIOSIMILAR PHARMACEUTICALS; ERYTHROPOIETIN; HEMATINICS; HUMANS; HYPERTENSION; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RENAL INSUFFICIENCY, CHRONIC;

EID: 84925223869     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD010590.pub2     Document Type: Article

References (379)

1. Akiba T, Akizawa T, Kakuma T. Randomized double-blind comparative study of recombinant human erythropoietin (epoetin kappa, produced by serum-free culture) in renal anemia patients on hemodialysis. Japanese Pharmacology & Therapeutics 2010;38(2):181-98. [EMBASE: 2010186120]
2. Akaishi M, Hiroe M, Hada Y, Suzuki M, Tsubakihara Y, Akizawa T, et al. Effect of anemia correction on left ventricular hypertrophy in patients with modestly high hemoglobin level and chronic kidney disease. Journal of Cardiology 2013;62(4):249-56. [MEDLINE: 23787155]
3. Akizawa T, Gejyo F, Nishi S, Iino Y, Watanabe Y, Saito A, et al. Positive outcomes of high hemoglobin target in patients with chronic kidney disease not on dialysis: a randomizedcontrolled study. Therapeutic Apheresis & Dialysis 2011;15 (5):431-40. [MEDLINE: 21974695]
4. Akizawa T, Tsubakihara Y. Target level for hemoglobin correction by darbepoetin alfa (KRN321) for patients with chronic kidney disease (CKD) not on dialysis in randomized controlled study; from the viewpoint of the efficacy [abstract no: SU-PO804]. Journal of the American Society of Nephrology 2007;18(Abstracts Issue):762A. [CENTRAL: CN-00740554]
5. Tsubakihara Y, Akizawa T. High target hemoglobin with erythropoiesis stimulating agent (ESA) in chronic kidney disease (CKD) slows the occurrence rate of events related to decline of renal function [abstract no: SA-FC341]. Journal of the American Society of Nephrology 2009;20:79A. [CENTRAL: CN-00793981]
6. Tsubakihara Y, Akizawa T. Target level for hemoglobin correction by darbepoetin alfa (KRN321) for patients with chronic kidney disease (CKD) not on dialysis in randomized controlled study; from the viewpoint of the safety [abstract no: SU-PO818]. Journal of the American Society of Nephrology 2007;18(Abstracts Issue):765A. [CENTRAL: CN-00740542]
7. Alexander M, Kewalramani R, Agodoa I, Globe D. Association of anemia correction with health related quality of life in patients not on dialysis. Current Medical Research & Opinion 2007;23(12):2997-3008. [MEDLINE: 17958944]
8. Thadhani R, Cheriyan R, Brenner R, Ford J, Powers K, Rahman SN. Treatment of anemia with ARANESP (darbepoetin alfa) improves health related quality of life (HRQOL) in patients with chronic kidney disease (CKD) [abstract]. Journal of the American Society of Nephrology 2002;13(September, Program & Abstracts): 637a. [CENTRAL: CN-00447983]
9. Allon M, Kleinman AK, Walczyk M, Kaupke C, Maroni BJ, Heatherington A, et al. The pharmacokinetics of novel erythropoiesis stimulating protein (NESP) following chronic intravenous administration is time-and doselinear [abstract no: A1308]. Journal of the American Society of Nephrology 2000;11(Sept):248A. [CENTRAL: CN-00626053]
10. Allon M, Kleinman K, Walczyk M, Kaupke C, Messer-Mann L, Olson K, et al. Pharmacokinetics and pharmacodynamics of darbepoetin alfa and epoetin in patients undergoing dialysis. Clinical Pharmacology & Therapeutics 2002;72(5):546-55. [MEDLINE: 12426518]
11. Chanu P, Gieschke R, Reigner B, Dougherty FC. Pharmacokinetic parameters of C.E.R.A. and are not affected by age in patients with chronic kidney disease on dialysis [abstract no: SaP351]. Nephrology Dialysis Transplantation 2007;22(Suppl 6):vi351. [CENTRAL: CN-00757500]
12. Chanu P, Gieschke R, Reigner B, Dougherty FC. Pharmacokinetics of C.E.R.A. and stable maintenance of haemoglobin (Hb) levels with once-monthly dosing in patients with chronic kidney disease (CKD) [abstract no: SaP325]. Nephrology Dialysis Transplantation 2007;22 (Suppl 6):vi342. [CENTRAL: CN-00757502]
13. Fishbane S, Dalton C, Beswick R, Dutka P, Schmidt R. Efficacy of C.E.R.A., a continuous erythropoietin receptor activator, in the treatment of renal anemia: overview of 6 global phase 3 trials [abstract no: 59]. American Journal of Kidney Diseases 2007;49(4):A39. [CENTRAL: CN-00756571]
14. Klinger M, Arias M, Vargemezis V, Besarab A, Sulowicz W, Gerntholtz T, et al. C.E.R.A. (Continuous Erythropoietin Receptor Activator) administered at extended intervals corrects Hb levels in patients with CKD on dialysis [abstract no: SA-PO212]. Journal of the American Society of Nephrology 2006;17(Abstracts):620A. [CENTRAL: CN-00644218]
15. Klinger M, Arias M, Vargemezis V, Besarab A, Sulowicz W, Gerntholtz T, et al. Efficacy of intravenous methoxy polyethylene glycol-epoetin beta administered every 2 weeks compared with epoetin administered 3 times weekly in patients treated by hemodialysis or peritoneal dialysis: a randomized trial. American Journal of Kidney Diseases 2007; 50(6):989-1000. [MEDLINE: 18037099]
16. Provenzano R, Macdougall IC, Law A, Ouyang Y, Bexon M. Anemia correction with C.E.R.A. in patients (pts) with chronic kidney disease (CKD) is unaffected by baseline hemoglobin (Hb) level [abstract no: SU-PO796]. Journal of the American Society of Nephrology 2007;18(Abstracts Issue): 760A. [CENTRAL: CN-00747311]
17. Arabul M, Gullulu M, Yilmaz Y, Eren MA, Baran B, Gul CB, et al. Influence of erythropoietin therapy on serum prohepcidin levels in dialysis patients. Medical Science Monitor 2009;15(11):CR583-7. [MEDLINE: 19865058]
18. Fishbane S, Dalton C, Beswick R, Dutka P, Schmidt R. Efficacy of C.E.R.A., a continuous erythropoietin receptor activator, in the treatment of renal anemia: overview of 6 global phase 3 trials [abstract no: 59]. American Journal of Kidney Diseases 2007;49(4):A39. [CN-00756571]
19. Kessler M, Martinez-Castelao A, Siamopoulos KC, Villa G, Spinowitz B, Dougherty FC, et al. C.E.R.A. once every 4 weeks in patients with chronic kidney disease not on dialysis: The ARCTOS extension study. Hemodialysis International 2010;14(2):233-9. [MEDLINE: 19888948]
20. Macdougall IC,Walker R, Provenzano R, de Alvaro F, Locay HR, Nader PC, et al. C.E.R.A. (Continuous Erythropoietin Receptor Activator) administered at extended intervals corrects anemia and maintains stable Hb levels in patients with CKD not on dialysis [abstract no: SA-PO208]. Journal of the American Society of Nephrology 2006;17(Abstracts): 619A.
21. Macdougall IC, Walker R, Provenzano R, de Alvaro F, Locay HR, Nader PC, et al. C.E.R.A. corrects anemia in patients with chronic kidney disease not on dialysis: results of a randomized clinical trial. Clinical Journal of The American Society of Nephrology: CJASN 2008;3(2):337-47. [MEDLINE: 18287255]
22. Provenzano R, Macdougall IC, Law A, Ouyang Y, Bexon M. Anemia correction with C.E.R.A. in patients (pts) with chronic kidney disease (CKD) is unaffected by baseline hemoglobin (Hb) level [abstract no: SU-PO796]. Journal of the American Society of Nephrology 2007;18(Abstracts Issue): 760A. [CENTRAL: CN-00747311]
23. Walker R, Macdougall IC, Levin A, Kessler M, Noble S, Burgos-Calderon R, et al. C.E.R.A. corrects anaemia and maintains stable haemoglobin (Hb) levels at extended administration intervals in a 52-week study of patients with chronic kidney disease (CKD) not on dialysis [abstract no: SuO003]. Nephrology Dialysis Transplantation 2007;22 (Suppl 6):vi412. [CENTRAL: CN-00644215]
24. Bahlmann J, Schöter KH, Scigalla P, Gurland HJ, Hilfenhaus M, Koch KM, et al. Morbidity and mortality in hemodialysis patients with and without erythropoietin treatment: a controlled study. Contributions to Nephrology 1991;88:90-106. [MEDLINE: 2040200]
25. Bennett WM. A multicenter clinical trial of epoetin beta for anemia of end-stage renal disease. Journal of the American Society of Nephrology 1991;1(7):990-8. [MEDLINE: 1883969]
26. Brown CD, Zhao ZH, Thomas LL, Friedman EA. Erythropoietin delays the onset of uremia in anemic azotemic diabetic predialysis patients [abstract]. Journal of the American Society of Nephrology 1995;6(3):447. [CENTRAL: CN-00483340]
27. Anonymous. Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. Canadian Erythropoietin Study Group. BMJ 1990;300(6724):573-8. [MEDLINE: 2108751]
28. Anonymous. Effect of recombinant human erythropoietin therapy on blood pressure in hemodialysis patients. Canadian Erythropoietin Study Group. American Journal of Nephrology 1991;11(1):23-6. [MEDLINE: 2048574]
29. Canadian Erythropoietin Study Group. The clinical effects and side-effects of recombinant human erythropoietin (EPO) in anaemic patients on chronic hemodialysis [abstract]. Kidney International 1990;37:278. [CENTRAL: CN-00583134]
30. Canadian Erythropoietin Study Group. The effect of recombinant human erythropoietin (EPO) upon quality of life and exercise capacity of anemic patients on chronic hemodialysis [abstract]. Kidney International 1990;37:278. [CENTRAL: CN-00583135]
31. Keown PA. Quality of life in end-stage renal disease patients during recombinant human erythropoietin therapy. The Canadian Erythropoietin Study Group. Contributions to Nephrology 1991;88:81-9. [MEDLINE: 2040199]
32. Keown PA, Canadian Erythropoietin Study Group. The effect of recombinant human erythropoietin (EPO) upon quality of life (QL) and functional capacity (FC) of anemic patients on chronic hemodialysis [abstract]. Kidney International 1989;35(1):195. [CENTRAL: CN-00583136]
33. Keown PA, Churchill DN, Poulin-Costello M, Lei L, Gantotti S, Agodoa I, et al. Dialysis patients treated with Epoetin alfa show improved anemia symptoms: A new analysis of the Canadian Erythropoietin Study Group trial. Hemodialysis International 2010;14(2):168-73. [MEDLINE: 20345390]
34. Laupacis A. A randomized double-blind study of recombinant human erythropoietin in anaemic hemodialysis patients. Canadian Erythropoietin Study Group. Transplantation Proceedings 1991;23(2):1825-6. [MEDLINE: 2053167]
35. Laupacis A. Changes in quality of life and functional capacity in hemodialysis patients treated with recombinant human erythropoietin. The Canadian Erythropoietin Study Group. Seminars in Nephrology 1990;10(2 Suppl 1):11-9. [MEDLINE: 2192412]
36. Laupacis A, Wong C, Churchill D. The use of generic and specific quality-of-life measures in hemodialysis patients treated with erythropoietin. The Canadian Erythropoietin Study Group. Controlled Clinical Trials 1991;12(4 Suppl): 168S-79S. [MEDLINE: 1663853]
37. Muirhead N, Keown P, Churchill DN, Lei L, Gitlin M, Mayne TJ. An intent-to-treat (ITT) analysis of anemia symptoms in the Canadian erythropoietin study group (CESG) [abstract no: PUB537]. Journal of the American Society of Nephrology 2008;19(Abstracts Issue):932A. [CENTRAL: CN-00790629]
38. Muirhead N, Keown P, Gitlin M,Mayne TJ, Churchill DN. A reanalysis of the Canadian erythropoietin study group (CESG) patient-reported outcomes (PRO) trial [abstract no: 177]. American Journal of Kidney Diseases 2008;51(4): A72. [CENTRAL: CN-00790972]
39. Muirhead N, Keown P, Lei L, Gitlin M, Mayne TJ, Churchill D. The relationship between achieved hemoglobin (HB) & exercise tolerance [abstract no: 161]. American Journal of Kidney Diseases 2008;51(4):A68. [CENTRAL: CN-00796608]
40. Muirhead N, Keown PA, Churchill DN, Poulin-Costello M, Gantotti S, Lei L, et al. Dialysis patients treated with Epoetin alpha show improved exercise tolerance and physical function: A new analysis of the Canadian Erythropoietin Study Group trial. Hemodialysis International 2011;15(1): 87-94. [EMBASE: 2011063916]
41. Muirhead N, Laupacis A, Wong C. Erythropoietin for anaemia in haemodialysis patients: results of a maintenance study (the Canadian Erythropoietin Study Group). Nephrology Dialysis Transplantation 1992;7(8):811-6. [MEDLINE: 1325613]
42. Chen HH, Tarng DC, Lee KF, Wu CY, Chen YC. Epoetin alfa and darbepoetin alfa: effects on ventricular hypertrophy in patients with chronic kidney disease. Journal of Nephrology 2008;21(4):543-9. [MEDLINE: 18651544]
43. Chen N, Qian JQ, Mei CL, Zhang AH, Xing CY, Wang L, et al. The efficacy and safety of continuous erythropoietin receptor activator in dialytic patients with chronic renal anemia: an open, randomized, controlled, multi-center trial. Chung-Hua Nei Ko Tsa Chih [Chinese Journal of Internal Medicine] 2012;51(7):502-7. [MEDLINE: 22943819]
44. Clyne N, Jogestrand T. Effect of erythropoietin treatment on physical exercise capacity and on renal function in predialytic uremic patients. Nephron 1992;60(4):390-6. [MEDLINE: 1584314]
45. Martinez-Castelao A. C.E.R.A. once every 4 weeks (Q4W) corrects anaemia in chronic kidney disease (CKD) patients with low incidence of HB values outside the target range [abstract no: OSu057]. NDT Plus 2010;3(Suppl 3):iii298. [EMBASE: 70484207]
46. Roger S. C.E.R.A. once every 4 weeks (Q4W) corrects anaemia in patients with chronic kidney disease (CKD) not on dialysis and demonstrates comparable safety to darbepoetin alfa [abstract no: 202]. Nephrology 2010;15 (Suppl 4):79-80. [EMBASE: 70467206]
47. Roger SD. C.E.R.A. once every 4 weeks (Q4W) corrects anaemia in patients with chronic kidney disease (CKD) not on dialysis and demonstrates comparable safety to darbepoetin alfa weekly (QW) or once every 2 weeks (Q2W) [abstract no: Sa535]. NDT Plus 2010;3(Suppl 3): iii219-20. [EMBASE: 70484001]
48. Roger SD, Locatelli F, Woitas RP, Laville M, Tobe SW, Provenzano R, et al. C.E.R.A. once every 4 weeks corrects anaemia and maintains haemoglobin in patients with chronic kidney disease not on dialysis. Nephrology Dialysis Transplantation 2011;26(12):3980-6. [MEDLINE: 21505096]
49. Coyne DW, Ling BN, Toto R, McDermott-Vitak AD, Trotman ML, Jackson L. Novel erythropoiesis stimulating protein (NESP) corrects anemia in dialysis patients when administered at reduced dose frequency compared with recombinant-human erythropoietin (r-huEPO) [abstract no: 1380]. Journal of the American Society of Nephrology 2000;11(Sept):263A. [CENTRAL: CN-00583382]
50. Coyne D, Zeig R, Benz R, Berns J, Varma N, Nakanishi A, et al. A randomized, double-blind study comparing darbepoetin alfa and recombinant human erythropoietin (rHuEPO) in the treatment of anemia in African-American (AA) subjects with chronic kidney disease (CKD) receiving hemodialysis (HD) [abstract no: TH-PO365]. Journal of the American Society of Nephrology 2006;17(Abstracts): 184A. [CENTRAL: CN-00740574]
51. Emans ME, Braam B, Diepenbroek A, van der Putten K, Cramer MJ, Wielders JP, et al. Neutrophil gelatinaseassociated lipocalin (NGAL) in chronic cardiorenal failure is correlated with endogenous erythropoietin levels and decreases in response to low-dose erythropoietin treatment. Kidney & Blood Pressure Research 2013;36(1):344-54. [MEDLINE: 23235391]
52. Emans ME, van der Putten K, Velthuis BK, de Vries JJ, Cramer MJ, America YG, et al. Atherosclerotic renal artery stenosis is prevalent in cardiorenal patients but not associated with left ventricular function and myocardial fibrosis as assessed by cardiac magnetic resonance imaging. BMC Cardiovascular Disorders 2012;12:76. [MEDLINE: 22989293]
53. Emans ME, van der Putten K, van Rooijen KL, Kraaijenhagen RJ, Swinkels D, van Solinge WW, et al. Determinants of red cell distribution width (RDW) in cardiorenal patients: RDW is not related to erythropoietin resistance. Journal of Cardiac Failure 2011;17(8):626-33. [MEDLINE: 21807323]
54. Jie KE, van der Putten K, Bergevoet MW, Doevendans PA, Gaillard CA, Braam B, et al. Short-and long-term effects of erythropoietin treatment on endothelial progenitor cell levels in patients with cardiorenal syndrome. Heart 2011; 97(1):60-5. [MEDLINE: 21071558]
55. Jie KE, van der Putten K, Wesseling S, Joles JA, Bergevoet MW, Pepers-de Kort F, et al. Short-term erythropoietin treatment does not substantially modulate monocyte transcriptomes of patients with combined heart and renal failure. PloS ONE 2012;7(9):e41339. [MEDLINE: 22957013]
56. van der Putten K, Jie KE, Emans ME, Verhaar MC, Joles JA, Cramer MJ, et al. Erythropoietin treatment in patients with combined heart and renal failure: objectives and design of the EPOCARES study. Journal of Nephrology 2010;23 (4):363-8. [MEDLINE: 20383871]
57. van der Putten K, Jie KE, van den Broek D, Kraaijenhagen RJ, Laarakkers C, Swinkels DW, et al. Hepcidin-25 is a marker of the response rather than resistance to exogenous erythropoietin in chronic kidney disease/chronic heart failure patients. European Journal of Heart Failure 2010;12 (9):943-50. [MEDLINE: 20601671]
58. van der Putten K, van den Broek D, van Rooijen KL, Kraaijenhagen RJ, Swinkels DW, Braam B, et al. Erythropoetin (EPO) induced decrease in hepcidin determines bone marrow response in patients with combined heart and renal failure [abstract no: SA-PO2668]. Journal of the American Society of Nephrology 2008;19 (Abstracts Issue):712A. [CENTRAL: CN-00765053]
59. Gertz B, Kes P, Essaian A, Bias P, Buchner A, Zellner D. Epoetin theta: efficacy and safety of subcutaneous administration in anemic pre-dialysis patients in the maintenance phase in comparison to epoetin beta. Current Medical Research & Opinion 2012;28(7):1101-10. [MEDLINE: 22533679]
60. Gertz B, Kohler E, Kes P, Essaian A, Bias P, Buchner A, et al. Epoetin theta: efficacy and safety of IV administration in anaemic haemodialysis patients in the maintenance phase in comparison to epoetin beta. Current Medical Research & Opinion 2010;26(10):2393-402. [MEDLINE: 20812790]
61. Goh BL, Ong LM, Sivanandam S, Lim TO, Morad Z, Biogeneric EPO Study Group. Randomized trial on the therapeutic equivalence between Eprex and GerEPO in patients on haemodialysis. Nephrology 2007;12(5):431-6. [MEDLINE: 17803464]
62. Haag-Weber M, Vetter A, Thyroff-Friesinger U, INJStudy Group. Therapeutic equivalence, long-term efficacy and safety of HX575 in the treatment of anemia in chronic renal failure patients receiving hemodialysis. Clinical Nephrology 2009;72(5):380-90. [MEDLINE: 19863881]
63. Vetter A, Haag-Weber M, Thyroff-Friesinger U. Efficacy and safety of intravenous (IV) HX575 (Binocrita) in the treatment of anaemia in hemodialysis patients [abstract no: SA-PO2660]. Journal of the American Society of Nephrology 2008;19(Abstracts Issue):710A. [CENTRAL: CN-00747269]
64. Haag-Weber M, Eckardt KU, Horl WH, Roger SD, Vetter A, Roth K. Safety, immunogenicity and efficacy of subcutaneous biosimilar epoetin-alpha (HX575) in non-dialysis patients with renal anemia: a multi-center, randomized, double-blind study. Clinical Nephrology 2012; 77(1):8-17. [MEDLINE: 22185963]
65. Hirakata H, Gejyo F, Suzuki M, Saito A, Lino Y, Watanabe Y, et al. Effect of darbepoetin alfa (KRN321) subcutaneous treatment on hemoglobin levels, health-related QOL (HRQOL) and left ventricular mass index (LVMI) in patients with chronic kidney disease (CKD) not on dialysis [abstract no: SA-PO204]. Journal of the American Society of Nephrology 2006;17(Abstracts):618A. [CENTRAL: CN-00740524]
66. Hirakata H, Tsubakihara Y, Gejyo F, Nishi S, Iino Y, Watanabe Y, et al. Maintaining high hemoglobin levels improved the left ventricular mass index and quality of life scores in pre-dialysis Japanese chronic kidney disease patients. Clinical & Experimental Nephrology 2010;14(1): 28-35. [MEDLINE: 19763743]
67. Inaguma D, Tsubakihara Y, Hirakata H, Hiroe M, Hada Y, Akizawa T, et al. Monthly subcutaneous treatment of darbepoetin alfa (KRN321) could maintain higher Hb safely and have beneficial effects on cardiac function of Japanese CKD patients not on dialysis [abstract no: SaP353]. Nephrology Dialysis Transplantation 2007;22 (Suppl 6):vi352. [CENTRAL: CN-00740573]
68. Suzuki M, Hada Y, Akaishi M, Hiroe M, Aonuma K, Tsubakihara Y, et al. Effects of anemia correction by erythropoiesis-stimulating agents on cardiovascular function in non-dialysis patients with chronic kidney disease. International Heart Journal 2012;53(4):238-43. [MEDLINE: 22878802]
69. Hori K, Tsujimoto Y, Ohmori H, Nakamura H, Suga A, Iwasaki M, et al. Randomized, double-blind, comparative study of intravenous KRN321 (darbepoetin alfa) compared to intravenous recombinant human erythropoietin (rHuEPO) for treatment of anemia in subjects with chronic renal failure (CRF) receiving hemodialysis in Japan [abstract no: F-PO502]. Journal of the American Society of Nephrology 2004;15(Oct):177A. [CENTRAL: CN-00740529]
70. Kleinman KS, Schweitzer SU. Human recombinant erythropoietin (rHuEPO) treatment of severe anemia associated with progressive renal failure may delay the need to initiate regular dialytic therapy [abstract]. Kidney International 1990;37(1):240. [CENTRAL: CN-00626057]
71. Kleinman KS, Schweitzer SU, Perdue ST, Abels RI. The use of recombinant human erythropoietin in the correction of anemia in pre-dialysis patients and its effects on renal function: a double blind placebo controlled trial [abstract]. Kidney International 1989;35(1):229. [CENTRAL: CN-00636148]
72. Kleinman KS, Schweitzer SU, Perdue ST, Bleifer KH, Abels RI. The use of recombinant human erythropoietin in the correction of anemia in predialysis patients and its effect on renal function: a double-blind, placebo-controlled trial. American Journal of Kidney Diseases 1989;14(6):486-95. [MEDLINE: 2688405]
73. Klinkmann H, Schmidt R, Wieczorek L, Scigalla P. Adverse events of subcutaneous recombinant human erythropoietin therapy. Contributions to Nephrology 1992;100:127-38. [MEDLINE: 1458898]
74. Klinkmann H, Wieczorek L, Scigalla P. Adverse events of subcutaneous recombinant human erythropoietin therapy: results of a controlled multicenter European study. Artificial Organs 1993;17(4):219-25. [MEDLINE: 8498900]
75. Baldamus C, Krivoshiev S, Wolf-Pflugmann M, Siebert-Weigel M, Koytchev R, Bronn A. Long-term safety and tolerability of epoetin zeta, administered intravenously, for maintenance treatment of renal anemia. Advances in Therapy 2008;25(11):1215-28. [MEDLINE: 18931828]
76. Krivoshiev S, Todorov VV, Manitius J, Czekalski S, Scigalla P, Koytchev R, et al. Comparison of the therapeutic effects of epoetin zeta and epoetin alpha in the correction of renal anaemia. Current Medical Research & Opinion 2008; 24(5):1407-15. [MEDLINE: 18394266]
77. Krivoshiev S, Wizemann V, Czekalski S, Schiller A, Pljesa S, Wolf-Pflugmann M, et al. Therapeutic equivalence of epoetin zeta and alfa, administered subcutaneously, for maintenance treatment of renal anemia. Advances in Therapy 2010;27(2):105-17. [MEDLINE: 20369312]
78. Kuriyama S, Tomonari H, Hashimoto T, Kawaguchi Y, Sakai O. Reversal of anemia by EPO therapy retards the progression of chronic renal failure in non-diabetic predialysis patients [abstract]. Nephrology 1997;3(Suppl 1): S506. [CENTRAL: CN-00461123]
79. Kuriyama S, Tomonari H, Yoshida H, Hashimoto T, Kawaguchi Y, Sakai O. Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients. Nephron 1997;77(2): 176-85. [MEDLINE: 9346384]
80. Li WY, Chu TS, Huang JW,Wu MS,Wu KD. Randomized study of darbepoetin alfa and recombinant human erythropoietin for treatment of renal anemia in chronic renal failure patients receiving peritoneal dialysis. Journal of the Formosan Medical Association 2008;107(11):843-50. [MEDLINE: 18971153]
81. Johnson DW, European/Australian NESP 980202 Study Group. Novel erythropoiesis stimulating protein (darbepoietin alpha) corrects anaemia of early chronic kidney disease (CKD) at a reduced dose frequency compared with recombinant human erythropoietin (rHuEPO) [abstract no: P156]. Nephrology 2002;7(Suppl 3):A40. [CENTRAL: CN-00794721]
82. Locatelli F, European/Australian NESP 980202 Study Group. Novel erythoropoiesis stimulating protein (NESP) corrects anemia of chronic renal insufficiency (CRI) at a reduced dose frequency compared with rHuEPO [abstract]. Nephrology Dialysis Transplantation 2001;16(6):A92. [CENTRAL: CN-00671771]
83. Locatelli F, Olivares J, Walker R, Wilkie M, European/ Australian NESP 980202 Study Group. Novel erythropoiesis stimulating protein (NESP) administered subcutaneously corrects anemia in subjects with chronic renal insufficiency (CRI) when administered at a reduced dose frequency compared with recombinant-human erythropoietin (r-huEPO) [abstract]. Journal of the American Society of Nephrology 2000;11(Sept):283A. [CENTRAL: CN-00626023]
84. Locatelli F, Olivares J, Walker R, Wilkie M, Jenkins B, Dewey C, et al. Novel erythropoiesis stimulating protein for treatment of anemia in chronic renal insufficiency. Kidney International 2001;60(2):741-7. [MEDLINE: 11473657]
85. Martin KJ. Epoetin delta for the management of renal anemia: a one year study [abstract no: TH-PO374]. Journal of the American Society of Nephrology 2006;17(Abstracts): 186A. [CN-00765049]
86. Martin KJ. The first human cell line-derived erythropoietin, epoetin-delta (Dynepo), in the management of anemia in patients with chronic kidney disease. Clinical Nephrology 2007;68(1):26-31. [MEDLINE: 17703832]
87. Martin KJ, Epoetin Delta 3001 Study Group. Epoetin delta in the management of renal anaemia: results of a 6-month study. Nephrology Dialysis Transplantation 2007;22 (10):3052-4. [MEDLINE: 17660186]
88. Smyth M, Pratt RD. Epoetin delta, erythropoietin produced in a human cell line, is as effective as epoetin alfa in the treatment of anemia [abstract no: 1296]. Blood 2006;108 (11):380a. [CENTRAL: CN-00740519]
89. Barany P, Besarab A, Macdougall IC, Law A, Ouyang Y, Heifets M. Median hemoglobin (Hb) decline following C.E.R.A. dose interruption is similar to that with other erythropoiesis stimulating agents (ESAs) [abstract no: SUPO795]. Journal of the American Society of Nephrology 2007; 18(Abstracts Issue):760A. [CENTRAL: CN-00794522]
90. Chanu P, Gieschke R, Reigner B, Dougherty FC. Pharmacokinetic parameters of C.E.R.A. and are not affected by age in patients with chronic kidney disease on dialysis [abstract no: SaP351]. Nephrology Dialysis Transplantation 2007;22(Suppl 6):vi351. [CENTRAL: CN-00757500]
91. Chanu P, Gieschke R, Reigner B, Dougherty FC. Pharmacokinetics of C.E.R.A. and stable maintenance of haemoglobin (Hb) levels with once-monthly dosing in patients with chronic kidney disease (CKD) [abstract no: SaP325]. Nephrology Dialysis Transplantation 2007;22 (Suppl 6):vi342. [CENTRAL: CN-00757502]
92. Fishbane S, Bernardo M, Locatelli F, del Aguila M, Edwardes M, Bexon M. Once-monthly intravenous (IV) C.E.R.A. maintains stable hemoglobin (Hb) in dialysis patients (pts), irrespective of age or gender [abstract no: SUPO779]. Journal of the American Society of Nephrology 2007; 18(Abstracts Issue):756A. [CENTRAL: CN-00757405]
93. Fishbane S, Dalton C, Beswick R, Dutka P, Schmidt R. Efficacy of C.E.R.A., a continuous erythropoietin receptor activator, in the treatment of renal anemia: overview of 6 global phase 3 trials [abstract no: 59]. American Journal of Kidney Diseases 2007;49(4):A39. [CENTRAL: CN-00756571]
94. Fishbane S, Levin NW, Mann JFE, Lewis JL, Bernardo M, Lunde NM, et al. IV C.E.R.A. (Continuous Erythropoietin Receptor Activator) once every 2 weeks or once monthly maintains stable Hb levels after converting directly from IV epoetin 1-3 times per week in patients with CKD on dialysis [abstract no: SA-PO205]. Journal of the American Society of Nephrology 2006;17(Abstracts):618A. [CENTRAL: CN-00757097]
95. Imbasciati E, Bernardo M, Caraman P, David-Neto E, Harris K, Law A, et al. Stable haemoglobin (Hb) levels are maintained with once-monthly C.E.R.A. in dialysis patients with varying C-reactive protein (CRP), albumin or dialysis adequacy [abstract no: SuO005]. Nephrology Dialysis Transplantation 2007;22(Suppl 6):vi412. [CENTRAL: CN-00758076]
96. Levin NW, Fishbane S, Canedo FV, Zeig S, Nassar GM, Moran JE, et al. Intravenous methoxy polyethylene glycolepoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis: a randomised non-inferiority trial (MAXIMA). Lancet 2007;370(9596):1415-21. [MEDLINE: 17950856]
97. Levin NW, Imbasciati E, Combe C, Rocco MV, Lok CE, Donnelly SM, et al. Adequate Hb levels are maintained with IV C.E.R.A. (Continuous Erythropoietin Receptor Activator) administered up to once monthly in dialysis patients irrespective of age, gender or diabetic status [abstract no: SA-PO206]. Journal of the American Society of Nephrology 2006;17(Abstracts):619A. [CENTRAL: CN-00755210]
98. Mann J, Locatelli F, Sulowicz W, Nissenson A, Portoles J, Levin N, et al. C.E.R.A. provides stable haemoglobin (Hb) levels in CKD patients on dialysis with and without coronary artery disease (CAD) or diabetes mellitus (DM) when administered once monthly [abstract no: SuO002]. Nephrology Dialysis Transplantation 2007;22(Suppl 6): vi411. [CENTRAL: CN-00791257]
99. Ryckelynck JP, Valdes Canedo F, Riella M, Lempert K, Donnelly S, Adrogue H, et al. Once-monthly C.E.R.A. maintains stable haemoglobin concentrations in dialysis patients regardless of gender or age [abstract no: SUO001]. Nephrology Dialysis Transplantation 2007;22(Suppl 6): vi411. [CENTRAL: CN-00644372]
100. Milutinovic S, Krpan D, Drenovac M. Erythropoietin (EPO) omega improves cognitive functioning and quality of life in dialysis patients in comparison to ALFA [abstract no: PUB233]. Journal of the American Society of Nephrology 2002;13(Program & Abstracts):718a. [CENTRAL: CN-00583281]
101. Milutinovic S, Milutinovic E, Plavljanic D, Kusec V. Differences in glycosylation structures have an important impact on potency and pharmacokinetics of erythropoietin (EPO) in dialyzed uremics [abstract]. Nephrology Dialysis Transplantation 2000;15(9):A156. [CENTRAL: CN-00461327]
102. Milutinovic S, Milutinovic E, Plavljanic D, Kusec V. Erythropoietin-induced hypertension in dialyzed uremics is influenced by glycosylation patterns of the molecule [abstract]. Nephrology Dialysis Transplantation 2001;16(6): A91. [CENTRAL: CN-00583279]
103. Milutinovic S, Milutinovic E, Plavljanic D, Kusec V. Molecular glycosylation patterns have an impact on erythropoietin-induced hypertension in dialyzed uremics [abstract]. Journal of the American Society of Nephrology 2001;12(Program & Abstracts):399A. [CENTRAL: CN-00626113]
104. Milutinovic S, Plavljani E, Trkulja V. Comparison of two epoetin brands in anemic hemodialysis patients: results of two efficacy trials and a single-dose pharmacokinetic study. Fundamental & Clinical Pharmacology 2006;20(5): 493-502. [MEDLINE: 16968421]
105. Milutinovic S, Trkulja V. Reduced responsiveness to epoetin at re-exposure after prolonged epoetin-free period in anemic hemodialysis patients with end-stage renal disease. CroatianMedical Journal 2006;47(3):424-32. [MEDLINE: 16758521]
106. Nissenson AR, Korbet S, Faber M, Burkart J, Gentile D, Hamburger R, et al. Multicenter trial of erythropoietin in patients on peritoneal dialysis. Journal of the American Society of Nephrology 1995;5(7):1517-29. [MEDLINE: 7703390]
107. Nissenson A, Krishnan M, Liu W, McCary L, Stehman-Breen C, Mix C. Hemoglobin (Hb) variability does not differ between hemodialysis (HD) patients treated with epoetin alfa and darbepoetin alfa [abstract no: TH-PO360]. Journal of the American Society of Nephrology 2006;17 (Abstracts):183A. [CENTRAL: CN-00740539]
108. Nissenson AR. Dosing darbepoetin alfa. American Journal of Kidney Diseases 2002;40(4):872. [MEDLINE: 12324929]
109. Nissenson AR, Swan SK, Lindberg JS, Soroka SD, Beatey R, Wang C, et al. Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients. American Journal of Kidney Diseases 2002;40(1): 110-8. [MEDLINE: 12087568]
110. Nissenson AR, Swan SK, Lindberg JS, Soroka SD, McDermott-Vitak AD, Wang C, et al. Novel Erythropoiesis stimulating protein (NESP) safely maintains hemoglobin concentration levels in hemodialysis patients as effectively as r-huEPO when administered once weekly [abstract no: A1326]. Journal of the American Society of Nephrology 2000; 11(Sept):252A. [CENTRAL: CN-00794722]
111. Nissenson AR, US/Canadian NESP 980117 Study Group. Once weekly IV novel erythoropoiesis stimulating protein (NESP) effectively maintains Hb in hemodialysis patients [abstract]. Nephrology Dialysis Transplantation 2001;16(6): A92. [CENTRAL: CN-00446969]
112. Palazzuoli A, Silverberg DS, Iovine F, Calabro A, Campagna MS, Gallotta M, et al. Effects of beta-erythropoietin treatment on left ventricular remodeling, systolic function, and B-type natriuretic peptide levels in patients with the cardiorenal anemia syndrome. American Heart Journal 2007;154(4):645.e9-15. [MEDLINE: 17892986]
113. Patel M, Thimons DG, Winston JL, Langholff W, McGowan T. An open-label, randomized, multicenter, controlled study of epoetin alfa for the treatment of anemia of chronic kidney disease in the long term care setting. Journal of the American Medical Directors Association 2012; 13(3):244-8. [MEDLINE: 21450214]
114. Carrera F.C.E.R.A. vs darbepoetin alfa as maintenance therapy for anaemia in patients with chronic kidney disease (CKD): The PATRONUS Study [abstract no: M558]. World Congress of Nephrology; 2009 May 22-26; Milan, Italy. 2009.
115. Carrera F, Lok CE, de Francisco A, Locatelli F, Mann JF, Canaud B, et al. Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycolepoetin beta versus darbepoetin alfa administered monthly: a randomized comparative trial. Nephrology Dialysis Transplantation 2010;25(12):4009-17. [MEDLINE: 20522670]
116. Locatelli F, PATRONUS Study Group. Once-monthly C.E.R.A. is superior to darbepoetin alfa for maintaining hemoglobin levels in hemodialysis patients regardless of age, gender, diabetic status or presence of hyperlipidemia [abstract no: SA-PO2412]. Journal of the American Society of Nephrology 2009;20:663A. [CENTRAL: CN-00747328]
117. Mann JF, PATRONUS Study Group. Risk factors for vascular events in hemodialysis patients receiving oncemonthly C.E.R.A. or once-monthly darbepoetin alfa: post hoc analysis of the PATRONUS Study [abstract no: PUB414]. Journal of the American Society of Nephrology 2009;20:921A. [CENTRAL: CN-00747329]
118. de Francisco AL, PATRONUS Study Group. Significantly higher hemoglobin response rates are achieved in hemodialysis patients with once-monthly C.E.R.A. compared with darbepoetin alfa in hemodialysis, regardless of etiology of chronic kidney disease [abstract no: SAPO2411]. Journal of the American Society of Nephrology 2009;20:663A. [CENTRAL: CN-00747327]
119. Barany P, Besarab A, Macdougall IC, Law A, Ouyang Y, Heifets M. Median hemoglobin (Hb) decline following C.E.R.A. dose interruption is similar to that with other erythropoiesis stimulating agents (ESAs) [abstract no: SUPO795]. Journal of the American Society of Nephrology 2007; 18(Abstracts Issue):760A. [CENTRAL: CN-00794522]
120. Chanu P, Gieschke R, Reigner B, Dougherty FC. Pharmacokinetic parameters of C.E.R.A. and are not affected by age in patients with chronic kidney disease on dialysis [abstract no: SaP351]. Nephrology Dialysis Transplantation 2007;22(Suppl 6):vi351. [CENTRAL: CN-00757500]
121. Chanu P, Gieschke R, Reigner B, Dougherty FC. Pharmacokinetics of C.E.R.A. and stable maintenance of haemoglobin (Hb) levels with once-monthly dosing in patients with chronic kidney disease (CKD) [abstract no: SaP325]. Nephrology Dialysis Transplantation 2007;22 (Suppl 6):vi342. [CENTRAL: CN-00757502]
122. Fishbane S, Dalton C, Beswick R, Dutka P, Schmidt R. Efficacy of C.E.R.A., a continuous erythropoietin receptor activator, in the treatment of renal anemia: overview of 6 global phase 3 trials [abstract no: 59]. American Journal of Kidney Diseases 2007;49(4):A39. [CENTRAL: CN-00756571]
123. Imbasciati E, Bernardo M, Caraman P, David-Neto E, Harris K, Law A, et al. Stable haemoglobin (Hb) levels are maintained with once-monthly C.E.R.A. in dialysis patients with varying C-reactive protein (CRP), albumin or dialysis adequacy [abstract no: SuO005]. Nephrology Dialysis Transplantation 2007;22(Suppl 6):vi412. [CENTRAL: CN-00758076]
124. Locatelli F, Sulowicz W, Harris K, Selgas R, Kaufman J, Klinger M, et al. SC C.E.R.A. (Continuous Erythropoietin Receptor Activator) once every 2 weeks or once monthly maintains stable Hb levels after converting directly from SC epoetin 1-3 times per week in patients with CKD on dialysis [abstract no: SA-PO207]. Journal of the American Society of Nephrology 2006;17(Abstracts):619A. [CENTRAL: CN-00626009]
125. Mann J, Locatelli F, Sulowicz W, Nissenson A, Portoles J, Levin N, et al. C.E.R.A. provides stable haemoglobin (Hb) levels in CKD patients on dialysis with and without coronary artery disease (CAD) or diabetes mellitus (DM) when administered once monthly [abstract no: SuO002]. Nephrology Dialysis Transplantation 2007;22(Suppl 6): vi411. [CENTRAL: CN-00791257]
126. Ryckelynck JP, Harris K, Selgas R, Stompor T, Ladanyi E, Opatrna S, et al. SC C.E.R.A. (Continuous Erythropoietin Receptor Activator) administered up to once monthly in patients with CKD on dialysis maintains adequate Hb levels regardless of age, gender or diabetic status [abstract no: SAPO210]. Journal of the American Society of Nephrology 2006; 17(Abstracts):620A. [CENTRAL: CN-00644371]
127. Ryckelynck JP, Valdes Canedo F, Riella M, Lempert K, Donnelly S, Adrogue H, et al. Once-monthly C.E.R.A. maintains stable haemoglobin concentrations in dialysis patients regardless of gender or age [abstract no: SUO001]. Nephrology Dialysis Transplantation 2007;22(Suppl 6): vi411. [CENTRAL: CN-00644372]
128. Sulowicz W, Locatelli F, Balla J, Csiky B, Rikker C, Aldigier J, et al. Subcutaneous (SC) C.E.R.A. (Continuous Erythropoietin Receptor Activator) administered once every 2 weeks or once monthly maintains haemoglobin (Hb) levels in patients with chronic kidney disease (CKD) on dialysis [abstract no: SP424]. Nephrology Dialysis Transplantation 2006;21(Suppl 4):iv156-7. [CENTRAL: CN-00601914]
129. Sulowicz W, Locatelli F, Ryckelynck JP, Balla J, Csiky B, Harris K, et al. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly. Clinical Journal of the American Society of Nephrology 2007;2(4):637-46. [MEDLINE: 17699476]
130. Benz R, Teehan B, Roth D, Buckalew V, Freedman B, Hatch F, et al. Renal function and quality of life (QOL) studies in anemic, pre-dialysis chronic renal failure (CRF) patients receiving recombinant human erythropoietin (r-HuEPO): results of a multi-center trial [abstract]. 12th International Congress of Nephrology; 1993 Jun 13-18; Jerusalem, Israel. 1993:316. [CENTRAL: CN-00602029]
131. Revicki DA, Brown RE, Feeny DH, Henry D, Teehan BP, Rudnick MR, et al. Health-related quality of life associated with recombinant human erythropoietin therapy for predialysis chronic renal disease patients. American Journal of Kidney Diseases 1995;25(4):548-54. [MEDLINE: 7702049]
132. Roth D, Smith RD, Schulman G, Steinman TI, Hatch FE, Rudnick MR, et al. Effects of recombinant human erythropoietin on renal function in chronic renal failure predialysis patients. American Journal of Kidney Diseases 1994;24(5):777-84. [MEDLINE: 7977319]
133. Barany P, Besarab A, Macdougall IC, Law A, Ouyang Y, Heifets M. Median hemoglobin (Hb) decline following C.E.R.A. dose interruption is similar to that with other erythropoiesis stimulating agents (ESAs) [abstract no: SUPO795]. Journal of the American Society of Nephrology 2007; 18(Abstracts Issue):760A. [CENTRAL: CN-00794522]
134. Fishbane S, Dalton C, Beswick R, Dutka P, Schmidt R. Efficacy of C.E.R.A., a continuous erythropoietin receptor activator, in the treatment of renal anemia: overview of 6 global phase 3 trials [abstract no: 59]. American Journal of Kidney Diseases 2007;49(4):A39. [CENTRAL: CN-00756571]
135. Spinowitz B, Coyne DW, Fraticelli M, Azer M, Dalal S, Villa G, et al. C.E.R.A. (continuous erythropoietin receptor activator) administered once every 2 weeks via pre-filled syringe (PFS) maintains stable Hb levels in patients with CKD on dialysis [abstract no: PUB376]. Journal of the American Society of Nephrology 2006;17(Abstracts):895A. [CENTRAL: CN-00653773]
136. Spinowitz B, Coyne DW, Lok CE, Fraticelli M, Azer M, Dalal S, et al. C.E.R.A. maintains stable control of hemoglobin in patients with chronic kidney disease on dialysis when administered once every two weeks. American Journal of Nephrology 2008;28(2):280-9. [MEDLINE: 18004064]
137. Shaheen FAM, Al-Aqeil N A, Badawi L, Sheikh IA, Shalabi NM, Adiku W, et al. Correction of anemia by erythropoietin in pre-dialysis patients. Saudi Kidney Diseases & Transplantation Bulletin 1993;4(3):215-9. [CENTRAL: CN-00525736]
138. Lynn KL, Buttimore AL, Inkster JA, Divakar D, Mylius AL, Ikram H, et al. Echocardiographic assessment of cardiac effects of erythropoietin in haemodialysis patients [abstract]. 9th Asian Colloquium in Nephrology; 1992 May 17-21; Seoul, Korea. 1992:183. [CENTRAL: CN-00461224]
139. Lynn KL, Richards AM, Buttimore AL, Inkster JA, Bailey RR, Robson RA, et al. Placebo-controlled study of blood pressure and vasoactive hormones in haemodialysis patients on erythropoietin [abstract]. 9th Asian Colloquium in Nephrology; 1992 May 17-21; Seoul, Korea. 1992:183. [: CN-00461225]
140. Shand B I, Buttimore AL, Hurrell MA, Wells JE, Inkster JA, Bailey RR, et al. Hemorheology and fistula function in home hemodialysis patients following erythropoietin treatment: a prospective placebo-controlled study. Nephron 1993;64(1):53-7. [MEDLINE: 7880205]
141. Sikole A, Polenakovic M, Spirovska V, Polenakovic B, Masin G. Analysis of heart morphology and function following erythropoietin treatment of anemic dialysis patients. Artificial Organs 1993;17(12):977-84. [MEDLINE: 8110072]
142. Sikole A, Polenakovic M, Spirovska V, Polenakovic B,Masin G. Echocardiographic analysis in patients on haemodialysis treated with erythropoietin [abstract]. Nephrology Dialysis Transplantation 1993;8(9):964. [CENTRAL: CN-00260828]
143. Pratt R. Pharmacokinetics of erythropoietin by a human cell line (Epoetin I): subcutaneous vs intravenous dosing in patients with chronic kidney disease [abstract no: 1137]. Haematologica 2006;91(Suppl 1):414. [CENTRAL: CN-00716122]
144. Pratt RD. Epoetin delta for the treatment of anemia in patients with CKD not requiring hemodialysis [abstract no: TH-PO377]. Journal of the American Society of Nephrology 2006;17(Abstracts):187A. [CENTRAL: CN-00765050]
145. Pratt RD, Dowell J. Pharmacokinetics of epoetin delta: a new erythropoietin produced by gene-activation in a human cell line [abstract no: TH-PO378]. Journal of the American Society of Nephrology 2006;17(Abstracts):187A. [CENTRAL: CN-00644158]
146. Smith WB, Dowell JA, Pratt RD. Pharmacokinetics and pharmacodynamics of epoetin delta in two studies in healthy volunteers and two studies in patients with chronic kidney disease. Clinical Therapeutics 2007;29(7):1368-80. [MEDLINE: 17825688]
147. Pratt R. Epoetin delta, erythropeitin produced by a human cell line, is effective in the treatment of renal anemia [abstract]. Haematologica 2006;91(Suppl):213. [CENTRAL: CN-00716123]
148. Spinowitz BS, Pratt RD, Epoetin Delta 2002 Study Group. Epoetin delta is effective for the management of anaemia associated with chronic kidney disease. Current Medical Research & Opinion 2006;22(12):2507-13. [MEDLINE: 17166333]
149. Barany P, Besarab A, Macdougall IC, Law A, Ouyang Y, Heifets M. Median hemoglobin (Hb) decline following C.E.R.A. dose interruption is similar to that with other erythropoiesis stimulating agents (ESAs) [abstract no: SUPO795]. Journal of the American Society of Nephrology 2007; 18(Abstracts Issue):760A. [CENTRAL: CN-00794522]
150. Canaud B, Braun J, Locatelli F, Villa G, Van Vlem B, Sanz Guajardo D, et al. Intravenous (IV) C.E.R.A. (continuous erythropoietin receptor activator) administered once every 2 weeks maintains stable haemoglobin (Hb) levels in patients with chronic kidney disease (CKD) on dialysis [abstract no: SP425]. Nephrology Dialysis Transplantation 2006;21(Suppl 4):iv157. [CENTRAL: CN-00690645]
151. Canaud B, Mingardi G, Braun J, Aljama P, Kerr PG, Locatelli F, et al. Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III study. Nephrology Dialysis Transplantation 2008; 23(11):3654-61. [MEDLINE: 18586762]
152. Fishbane S, Dalton C, Beswick R, Dutka P, Schmidt R. Efficacy of C.E.R.A., a continuous erythropoietin receptor activator, in the treatment of renal anemia: overview of 6 global phase 3 trials [abstract no: 59]. American Journal of Kidney Diseases 2007;49(4):A39. [CENTRAL: CN-00756571]
153. Teehan BP, Sigler MH, Brown JM, Benz RL, Gilgore GS, Schleifer CR, et al. Hematologic and physiologic studies during correction of anemia with recombinant human erythropoietin in predialysis patients. Transplantation Proceedings 1989;21(6 Suppl 2):63-6. [EMBASE: 1990284570]
154. Campistol JM, Carreno A,Morales JM, Pallardo L, Franco A, Navarro D, et al. Once-monthly pegylated epoetin beta versus darbepoetin alfa every two weeks in renal transplant recipients: a randomized trial. Transplantation 2013;95(2): e6-e10. [MEDLINE: 23325012]
155. Carreno A, Campistol JM, Arias M, Morales JM, Pallardo L, Franco A. A randomised, multicenter, phase IIIb clinical trial to evaluate efficacy and safety of C.E.R.A. once amonth versus darbepoetin alfa in renal transplant recipients with chronic renal anaemia (TIVOLI Study Group) [abstract no: F164]. NDT Plus 2011;4(Suppl 2):4.s2.32.
156. Carreno A, Campistol JM, Arias M, Morales JM, Pallardo L, Franco A. A randomised, multicenter, phase IIIb clinical trial to evaluate efficacy and safety of C.E.R.A. once a month versus darbepoetin alfa in renal transplant recipients with chronic renal anaemia (TIVOLI study group) [abstract no: 27]. American Journal of Transplantation 2011;11 (Suppl 2):36. [EMBASE: 70405062]
157. Tolman C, Richardson D, Bartlett C, Will E. A randomised study of weekly subcutaneous aranesp and neorecormon in a large unselected haemodialysis cohort, managed with computer assisted anaemia alogrithms [abstract]. 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15-18; Lisbon, Portugal. 2004:229-30. [CENTRAL: CN-00509514]
158. Tolman C, Richardson D, Bartlett C, Will E. Application of computer assisted anaemia management algorithms in haemodialysis patients produces predictable haemoglobin outcomes regardless of the erythropoietic agent or frequency of administration: results of a randomised study [abstract]. 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15-18; Lisbon, Portugal. 2004:110. [CENTRAL: CN-00509513]
159. Tolman C, Richardson D, Bartlett C, Will E. Structured conversion from thrice weekly to weekly erythropoietic regimens using a computerized decision-support system: a randomized clinical study. Journal of the American Society of Nephrology 2005;16(5):1463-70. [MEDLINE: 15788469]
160. Tolman C, Richardson D, Bartlett C, Will EJ. Dose conversion ratio (DCR) from subcutaneous epoetin-b (EPO) to weekly darbepoetin-a (DA) is dependent on baseline sensitivity: results from a randomised study [abstract no: SA-PO461]. Journal of the American Society of Nephrology 2004;15(Oct):404A. [CENTRAL: CN-00583282]
161. West RM, Harris K, Gilthorpe MS, Tolman C, Will EJ. Functional data analysis applied to a randomized controlled clinical trial in hemodialysis patients describes the variability of patient responses in the control of renal anemia. Journal of the American Society of Nephrology 2007;18(8):2371-6. [MEDLINE: 17625113]
162. Desai AS, Toto R, Jarolim P, Uno H, Eckardt KU, Kewalramani R, et al. Association between cardiac biomarkers and the development of ESRD in patients with type 2 diabetes mellitus, anemia, and CKD. American Journal of KidneyDiseases 2011;58(5):717-28. [MEDLINE: 21820220]
163. Lewis EF, Pfeffer MA, Feng A, Uno H, McMurray JJ, Toto R, et al. Darbepoetin alfa impact on health status in diabetes patients with kidney disease: a randomized trial. Clinical Journal of The American Society of Nephrology: CJASN 2011; 6(4):845-55. [MEDLINE: 21212421]
164. McMurray JJ, Uno H, Jarolim P, Desai AS, de Zeeuw D, Eckardt KU, et al. Predictors of fatal and nonfatal cardiovascular events in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia: an analysis of the Trial to Reduce cardiovascular Events with Aranesp (darbepoetin-alfa) Therapy (TREAT). American Heart Journal 2011;162(4):748-55. [MEDLINE: 21982669]
165. Mix TC, Brenner RM, Cooper ME, de Zeeuw D, Ivanovich P, Levey AS, et al. Rationale--Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney disease. American Heart Journal 2005;149(3): 408-13. [MEDLINE: 15864229]
166. Pfeffer MA, Burdmann EA, Chen C, Cooper ME, de Zeeuw D, Eckardt K, et al. Trial to reduce cardiovascular events with Aranesp therapy [abstract]. Circulation 2010; 120(21):2154-5. [EMBASE: 70089295]
167. Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. New England Journal of Medicine 2009;361(21):2019-32. [MEDLINE: 19880844]
168. Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, et al. Baseline characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). American Journal of Kidney Diseases 2009;54(1):59-69. [MEDLINE: 19501439]
169. Pfeffer MA, TREAT Executive Committee. An ongoing study of anemia correction in chronic kidney disease. New England Journal of Medicine 2007;356(9):959-61. [MEDLINE: 17329707]
170. Skali H, Lin J, Pfeffer MA, Chen CY, Cooper ME, McMurray JJ, et al. Hemoglobin stability in patients with anemia, CKD, and type 2 diabetes: an analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) placebo arm. American Journal of Kidney Diseases 2013;61(2):238-46. [MEDLINE: 23159232]
171. Skali H, Parving HH, Parfrey PS, Burdmann EA, Lewis EF, Ivanovich P, et al. Stroke in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia treated with darbepoetin alfa: the trial to reduce cardiovascular events with Aranesp therapy (TREAT) experience. Circulation 2011;124(25):2903-8. [MEDLINE: 22104547]
172. Solomon SD, Uno H, Lewis EF, Eckardt KU, Lin J, Burdmann EA, et al. Erythropoietic response and outcomes in kidney disease and type 2 diabetes. New England Journal of Medicine 2010;363(12):1146-55. [MEDLINE: 20843249]
173. Thomas MC, Cooper ME, Rossing K, Parving HH. Anaemia in diabetes: Is there a rationale to TREAT?. Diabetologia 2006;49(6):1151-7. [MEDLINE: 16586069]
174. Toto R, Ivanovich P, Levey A, Parfrey PS, Pereira BJ, Remuzzi G, et al. Trial to Reduce cardiovascular Events with Aranesp® (darbepoetin alfa) Therapy (TREAT) [abstract no: SU-PO239]. Journal of the American Society of Nephrology 2004;15(Oct):584A. [CENTRAL: CN-00550766]
175. Van Biesen W, Vanholder R, Veys N, Verbeke F, Lameire N. Efficacy of erythropoietin administration in the treatment of anemia immediately after renal transplantation. Transplantation 2005;79(3):367-8. [MEDLINE: 15699772]
176. Van Loo A, Vanholder R. Recombinant human erythropoietin (Rhu-EPO) corrects anaemia during the first weeks after renal transplantation (RTP) [abstract]. Nephrology Dialysis Transplantation 1996;11(6):A265. [CENTRAL: CN-00261322]
177. Van Loo A, Vanholder R, Bernaert P, De Roose J, Lameire N. Recombinant human erythropoietin corrects anaemia during the first weeks after renal transplantation: a randomized prospective study. Nephrology Dialysis Transplantation 1996;11(9):1815-21. [MEDLINE: 8918628]
178. Van Loo A, Vanholder R, Bernaert P, Lamiere N. Recombinant human erythropoietin (Rhu-EPO) corrects anaemia during the first weeks after renal transplantation (RTP) [abstract]. Nephrology Dialysis Transplantation 1997; 12(3):631. [CN-00261344]
179. Vanholder R, Bernaert P, Van Loo A, Lameire N, Ringoir S. Recombinant human erythropoietin corrects early posttransplantation anemia: a randomized prospective study [abstract]. Journal of the American Society of Nephrology 1995;6(3):1120. [CENTRAL: CN-00486286]
180. Canaud B. Darbepoetin alfa dose requirements for IV and SC administration are equivalent in anaemic dialysis patients [abstract no: M319]. Nephrology Dialysis Transplantation 2002;17(Suppl 12):137. [CENTRAL: CN-00550478]
181. Kerr PG, Harris D, Hawley C, Walker R, European/ Australian NESP 970290 Study Group. Novel erythropoiesis stimulating protein (NESP) maintains haemoglobin in ESRD patients with administered once weekly or once every other week [abstract no: 181]. Nephrology 2000;5(3):A112. [CENTRAL: CN-00509271]
182. Vanrenterghem Y, Barany P, Mann J, European/Australian NESP 970290 Study Group. Novel erythropoiesis stimulating protein (NESP) maintains hemoglobin (hgb) in ESRD patients when administered once weekly or once every other week [abstract]. Journal of the American Society of Nephrology 1999;10(Program & Abstracts):270A. [CENTRAL: CN-00583820]
183. Vanrenterghem Y, Barany P, Mann JF, Kerr PG, Wilson J, Baker NF, et al. Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients. Kidney International 2002;62(6):2167-75. [MEDLINE: 12427142]
184. Watson A, Gimenez L, Walser M, Cotton S, Spivak J. A prospective double-blind study of subcutaneous recombinant human erythropoietin in predialysis renal failure [abstract]. Journal of Clinical Pharmacology 1989;29 (929):856.
185. Watson AJ, Gimenez LF, Cotton S, Walser M, Spivak JL. Treatment of the anemia of chronic renal failure with subcutaneous recombinant human erythropoietin. American Journal of Medicine 1990;89(4):432-5. [MEDLINE: 2220877]
186. Acchiardo SR, Quinn BP, Moore LW, Burk LB, Miles DE. Evaluation of hemodialysis patients treated with erythropoietin. American Journal of Kidney Diseases 1991; 17(3):290-4. [MEDLINE: 1996571]
187. Laville M, Anaemia CORrection in Diabetes trial. New strategies in anaemia management: ACORD (Anaemia CORrection in Diabetes) trial. Acta Diabetologica 2004;41 Suppl 1:S18-22. [MEDLINE: 15103544]
188. Ritz E, Bilous R, O'Donoghue D, Laville M, de Alvaro F. Prescription patterns of cardio-and reno-protective agents in early diabetic nephropathy: baseline data from the ACORD trial [abstract no: PUB100]. Journal of the American Society of Nephrology 2004;15(Oct):783A. [CENTRAL: CN-00550505]
189. Ritz E, Bilous RW, de Alvaro F, Laville M, O'Donoghue D, Archerhag A. Anemia correction with epoetin beta in patients with diabetes and chronic kidney disease -primary results of the anaemia correction in diabetes (ACORD) study [abstract no: SO022]. Nephrology Dialysis Transplantation 2006;21(Suppl 4):iv11. [CENTRAL: CN-00763625]
190. Ritz E, Laville M, Bilous R W, O'Donoghue D, Scherhag A, Burger U, et al. Target level for hemoglobin correction in patients with diabetes and CKD: primary results of the Anemia Correction in Diabetes (ACORD) Study. American Journal of Kidney Diseases 2007;49(2):194-207. [MEDLINE: 17261422]
191. de Francisco AL, Sulowicz W, Dougherty FC. Subcutaneous CERA (continuous erythropoiesis receptor activator) has potent erythropoietic activity in dialysis patients with chronic renal anemia: an exploratory multiple-dose study [abstract]. Journal of the American Society of Nephrology 2003;14(Nov):27A-8A. [CENTRAL: CN-00550366]
192. de Francisco AL, Sulowicz W, Klinger M, Niemczyk S, Vargemezis V, Metivier F, et al. Continuous Erythropoietin Receptor Activator (C.E.R.A.) administered at extended administration intervals corrects anaemia in patients with chronic kidney disease on dialysis: a randomised, multicentre, multiple-dose, phase II study. International Journal of Clinical Practice 2006;60(12):1687-96. [MEDLINE: 17109676]
193. Besarab A, Beyer U, Dougherty FC. Long-term intravenous CERA (Continuous Erythropoietin Receptor Activator) maintains hemoglobin concentrations in hemodialysis patients [abstract no: W-PO40127]. Nephrology 2005;10 (Suppl 1):A312-3. [CENTRAL: CN-00747326]
194. Besarab A, Salifu MO, Lunde NM, Bansal V, Fishbane S, Dougherty FC, et al. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease. Clinical Therapeutics 2007;29(4): 626-39. [MEDLINE: 17617286]
195. Dougherty FC, Beyer U. No changes in blood pressure in dialysis patients after 12 months of treatment with IV/SC CERA (Continuous Erythropoietin Receptor Activator) [abstract no: W-PO40131]. Nephrology 2005;10(Suppl 1): A313-4. [CENTRAL: CN-00602138]
196. Dougherty FC, Beyer U. Safety and tolerability profile of continuous erythropoietin receptor activator (CERA) with extended dosing intervals in patients with chronic kidney disease on dialysis [abstract no: W-PO40130]. Nephrology 2005;10(Suppl 1):A313. [CENTRAL: CN-00602137]
197. Dougherty FC, Loghman-Adham M, Schultze N, Beyer U. Adequate hemoglobin levels are maintained with continuous erythropoietin receptor activator (CERA) in dialysis patients regardless of gender, age, race and diabetic status [abstract no: MP206]. Nephrology Dialysis Transplantation 2005;20 (Suppl 5):v269. [CENTRAL: CN-00602143]
198. Dutka P, Tilocca P, BA16285 and BA16286 Study Groups. CERA (Continuous Erythropoietin Receptor Activator) maintains stable hemoglobin concentrations in dialysis patients irrespective of gender, age, race or diabetic status [abstract]. Nephrology Nursing Journal 2006;33(2):138. [CENTRAL: CN-00602144]
199. Dougherty FC, Beyer U. No changes in blood pressure in dialysis patients after 12 months of treatment with IV/SC CERA (Continuous Erythropoietin Receptor Activator) [abstract no: W-PO40131]. Nephrology 2005;10(Suppl 1): A313-4. [CENTRAL: CN-00602138]
200. Dougherty FC, Beyer U. Safety and tolerability profile of continuous erythropoietin receptor activator (CERA) with extended dosing intervals in patients with chronic kidney disease on dialysis [abstract no: W-PO40130]. Nephrology 2005;10(Suppl 1):A313. [CENTRAL: CN-00602137]
201. Dougherty FC, Loghman-Adham M, Schultze N, Beyer U. Adequate hemoglobin levels are maintained with continuous erythropoietin receptor activator (CERA) in dialysis patients regardless of gender, age, race and diabetic status [abstract no: MP206]. Nephrology Dialysis Transplantation 2005;20 (Suppl 5):v269. [CENTRAL: CN-00602143]
202. Dutka P, Tilocca P, BA16285 and BA16286 Study Groups. CERA (Continuous Erythropoietin Receptor Activator) maintains stable hemoglobin concentrations in dialysis patients irrespective of gender, age, race or diabetic status [abstract]. Nephrology Nursing Journal 2006;33(2):138. [CENTRAL: CN-00602144]
203. Locatelli F, Villa G, Arias M, Marchesi D, Dougherty FC, Beyer U, et al. CERA (Continuous Erythropoietin receptor activator) maintains hemoglobin levels in dialysis patients when administered subcutaneously up to once every 4 weeks. [abstract no: SU-PO051]. Journal of the American Society of Nephrology 2004;15(Oct):543A. [CENTRAL: CN-00626008]
204. Locatelli F, Villa G, Beyer U, Dougherty FC. Subcutaneous CERA (Continuous Erythropoietin Receptor Activator) maintains hemoglobin concentrations with dosing intervals up to 4 weeks in dialysis patients [abstract no: MP183]. Nephrology Dialysis Transplantation 2005;20(Suppl 5):v261. [: CN-00602142]
205. Locatelli F, Villa G, de Francisco AL, Albertazzi A, Adrogue HJ, Dougherty FC, et al. Effect of a continuous erythropoietin receptor activator (C.E.R.A.) on stable haemoglobin in patients with CKD on dialysis: once monthly administration. Current Medical Research & Opinion 2007;23(5):969-79. [MEDLINE: 17519064]
206. Salifu M, Villa G, Dougherty FC. Adequate hemoglobin levels are maintained with continuous erythropoietin receptor activator (CERA) in dialysis patients with different ranges of iron status and pre-existing conditions. [abstract no: 138]. American Journal of Kidney Diseases 2006;47(4): A53. [CENTRAL: CN-00602141]
207. Berns JS, Rudnick MR, Cohen RM, Bower JD, Wood BC. Effects of normal hematocrit on ambulatory blood pressure in epoetin-treated hemodialysis patients with cardiac disease. Kidney International 1999;56(1):253-60. [MEDLINE: 10411700]
208. Berns JS, Rudnick MR, Cohen RM, Maloney A. Effect of normal v. anemic hematocrit on ambulatory blood pressure (ABP) in erythropoietin-treated hemodialysis (HD) patients [abstract]. Journal of the American Society of Nephrology 1995;6(3):520. [CENTRAL: CN-00483215]
209. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. New England Journal of Medicine 1998;339(9):584-90. [MEDLINE: 9718377]
210. Besarab A, Goodkin DA, Nissenson AR, Normal Hematocrit Cardiac Trial Authors. The normal hematocrit study--follow-up. New England Journal of Medicine 2008; 358(4):433-4. [MEDLINE: 18216370]
211. Conlon P, Kovalik E, Minda SN, Schumm D, Gutman R, Schwab SJ. Normalizing hematocrit in hemodialysis patients does not increase blood pressure [abstract]. Journal of the American Society of Nephrology 1995;6(3):526. [CENTRAL: CN-00483579]
212. Conlon PJ, Kovalik E, Schumm D, Minda S, Schwab SJ. Normalization of hematocrit in hemodialysis patients does not affect silent ischemia. Renal Failure 2000;22(2): 205-11. [MEDLINE: 10803764]
213. Conlon PJ, Kovalik E, Schumm D, Minda S, Schwab SJ. Normalization of hematocrit in hemodialysis patients with cardiac disease does not increase blood pressure. Renal Failure 2000;22(4):435-44. [MEDLINE: 10901181]
214. Coyne DW. The health-related quality of life was not improved by targeting higher hemoglobin in the Normal Hematocrit Trial. Kidney International 2012;82(2):235-41. [MEDLINE: 22437411]
215. Goodkin DA. The Normal Hematocrit Cardiac Trial revisited. Seminars in Dialysis 2009;22(5):495-502. [MEDLINE: 19650856]
216. Kilpatrick R, Critchlow C, Besarab A, Fishbane S, Stehman-Breen C, Krishnan M, et al. Epoetin alfa (EPO) responsiveness predicts survival in the normal hematocrit study (NHS) [abstract no: TH-PO382]. Journal of the American Society of Nephrology 2006;17(Abstracts):188A. [CENTRAL: CN-00615892]
217. Kilpatrick RD, Critchlow CW, Fishbane S, Besarab A, Stehman-Breen C, Krishnan M, et al. Greater epoetin alfa responsiveness is associated with improved survival in hemodialysis patients. Clinical Journal of The American Society of Nephrology: CJASN 2008;3(4):1077-83. [MEDLINE: 18417744]
218. Brier ME, Gaweda AE, Dailey A, Aronoff GR, Jacobs AA. Randomized trial of model predictive control for improved anemia management. Clinical Journal of The American Society of Nephrology: CJASN 2010;5(5):814-20. [MEDLINE: 20185598]
219. Dailey A, Gaweda A, Jacobs A, Aronoff G, Brier M. Computational intelligence based anemia management system for the dosing of erythropoietin [abstract no: FPO833]. Journal of the American Society of Nephrology 2007; 18(Abstracts):285A. [CENTRAL: CN-00774216]
220. Choukroun G, Kamar N, Dussol B, Etienne I, Cassuto-Viguier E, Toupance O, et al. Correction of postkidney transplant anemia reduces progression of allograft nephropathy. Journal of the American Society of Nephrology 2012;23(2):360-8. [MEDLINE: 22193388]
221. Choukroun G, Kamar N, Dussol B, Etienne I, Cassuto-Viguier E, Toupance O, et al. The complete correction of post-transplant anemia reduces the rate of progression of chronic allograft nephropathy [abstract no: 340]. American Journal of Transplantation 2010;10(Suppl 4):141. [EMBASE: 70463701]
222. Choukroun G, Kamar N, Dussol B, Etienne I, Cassuto-Viguier E, Toupance O, et al. The complete correction of post-transplant anemia reduces the rate of progression of chronic allograft nephropathy [abstract no: Sa667]. NDT Plus 2010;3(Suppl 3):iii267-8. [EMBASE: 70484133]
223. Choukroun G, Rostaing L, Dussol B, Etienne I, Cassuto E, Toupance O, et al. Anemia correction improves quality of life of renal transplant recipients: results of the CAPRIT study [abstract no: SA-FC440]. Journal of the American Society of Nephrology 2008;19(Abstracts Issue):99A-100A. [CENTRAL: CN-00724883]
224. Cassels C. CHOIR silenced as findings show increased risk of CVD outcomes/death. Medscape Medical News, 2006. http://www.medscape.com/viewarticle/539039 (accessed 2 October 2014).
225. Inrig JK, Barnhart HX, Reddan D, Patel UD, Sapp S, Califf RM, et al. Effect of hemoglobin target on progression of kidney disease: a secondary analysis of the CHOIR (Correction of Hemoglobin and Outcomes in Renal Insufficiency) trial. American Journal of Kidney Diseases 2012;60(3):390-401. [MEDLINE: 22537421]
226. Inrig JK, Sapp S, Barnhart H, Patel UD, Reddan D, Singh A, et al. Impact of higher hemoglobin targets on blood pressure and clinical outcomes: a secondary analysis of CHOIR. Nephrology Dialysis Transplantation 2012;27(9): 3606-14. [MEDLINE: 22573238]
227. McCullough PA, Barnhart HX, Inrig JK, Reddan D, Sapp S, Patel UD, et al. Cardiovascular toxicity of epoetin-alfa in patients with chronic kidney disease. American Journal of Nephrology 2013;37(6):549-58. [MEDLINE: 23735819]
228. Reddan D, Szczech L, Sapp S, Bhaduri S, Klausner M, Singh AK, et al. ECG abnormalities among CKD patients with Anemia: baseline data from the CHOIR study [abstract no: SU-PO241]. Journal of the American Society of Nephrology 2004;15(Oct):585A. [CENTRAL: CN-00550515]
229. Reddan D, Tran L, Singh A. Correction of hemoglobin and outcomes in renal insufficiency (CHOIR): study design [abstract]. American Journal of Kidney Diseases 2002;39(4): A27. [CENTRAL: CN-00402331]
230. Reddan D, Tran LL, Jollis J, Singh A. Anemia correction and left ventricular hypertrophy: an echocardiographic substudy of the correction of hemoglobin and outcomes in renal insufficiency (CHOIR) study [abstract no: PUB028]. Journal of the American Society of Nephrology 2002;13 (Program&Abstracts):676A. [CENTRAL: CN-00447363]
231. Singh AK, Bhaduri S, Tang KL, Klausner M, Corwin M, Reddan D. Factors associated with hemoglobin (HB) response in patients (pts) with anemia of chronic kidney disease (CKD) [abstract no: SA-PO726]. Journal of the American Society of Nephrology 2003;14(Nov):457A. [CENTRAL: CN-00550451]
232. Singh AK, Day B, Szczech L, Bhaduri S, Klausner M, Obeng A, et al. Iron deficiency in CKD patients: baseline data from the CHOIR study [abstract no: SU-PO240]. Journal of the American Society of Nephrology 2004;15(Oct): 585A. [CENTRAL: CN-00550452]
233. Singh AK, Day B, Szczech L, Bhaduri S, Klausner M, Reddan D, et al. Medication use among CKD patients with cardiac disease: baseline data from the CHOIR study [abstract no: PUB173]. Journal of the American Society of Nephrology 2004;15(Oct):799A. [CENTRAL: CN-00550455]
234. Singh AK, Day B, Szczech L, Bhaduri S, Klausner M, Reddan D, et al. Medication use among diabetic and nondiabetic CKD patients: baseline data from the CHOIR study [abstract no: SU-PO200]. Journal of the American Society of Nephrology 2004;15(Oct):575A-6A. [CENTRAL: CN-00550456]
235. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, et al. Correction of anemia with epoetin alfa in chronic kidney disease. New England Journal of Medicine 2006;355(20):2085-98. [MEDLINE: 17108343]
236. Singh AK, Szczech LA, Tang L, Sapp S, Wolfson M, Reddan DN. The effect of correcting anemia using epoietinalfa in patients with chronic kidney disease: results of the correction of hemoglobin and outcomes in renal insufficiency (CHOIR) study [abstract no: F-FC091]. Journal of the American Society of Nephrology 2006;17 (Abstracts):56A. [CENTRAL: CN-00601974]
237. Szczech L. Post hoc analysis of the associations between hemoglobin and outcomes in CHOIR [abstract]. Renal Week; 2007 Oct 31-Nov 5; San Francisco, CA. 2007. [CENTRAL: CN-00757554]
238. Szczech LA, Barnhart HX, Inrig JK, Reddan DN, Sapp S, Califf RM, et al. Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney International 2008;74(6):791-8. [MEDLINE: 18596733]
239. Szczech LA, Barnhart HX, Sapp S, Felker GM, Hernandez A, Reddan D, et al. A secondary analysis of the CHOIR trial shows that comorbid conditions differentially affect outcomes during anemia treatment. Kidney International 2010;77(3):239-46. [MEDLINE: 19890274]
240. Cianciaruso B, Ravani P, Barrett BJ, Levin A, ITA-EPO-7 investigators. Italian randomized trial of hemoglobin maintenance to prevent or delay left ventricular hypertrophy in chronic kidney disease. Journal of Nephrology 2008;21 (6):861-70. [MEDLINE: 19034870]
241. Cianciaruso B, Ravani P, Torraca S, Andreucci VE, ITA-7 Study Group. Effect of anemia correction with epoietin a (EPO) on left ventricular mass (LVM) in patients with chronic kidney disease (CKD): a multicenter randomized controlled trial [abstract no: SU-PO066]. Journal of the American Society of Nephrology 2004;15(Oct):547A. [CENTRAL: CN-00602132]
242. Clyne N, Drueke T, Eckardt K, Locatelli F, Macdougall I, Tsakiris D. Quality of life assessment in the 'cardiovascular risk reduction by early anaemia treatment with epoetin beta' (CREATE) study [abstract]. Nephrology Dialysis Transplantation 2003;18(Suppl 4):155-6. [CENTRAL: CN-00444859]
243. Clyne N, Drueke TB, Eckardt K, Locatelli F, Macdougall IC, Tsakiris D, et al. Diagnostic value of NT-proBNP in CKD patients: baseline and 6-month data from the CREATE Study [abstract no: F-PO320]. Journal of the American Society of Nephrology 2004;15(Oct):136A. [CENTRAL: CN-00550685]
244. Clyne N, Macdougall I, Bilous R, Ritz E, CREATE Study Group, ACORD Study Group. Haemoglobin control with epoetin beta: results from the Cardiovascular risk Reduction by Early Anaemia Treatment with Epoetin beta (CREATE) and Anaemia Correction in Diabetes (ACORD) studies [abstract no: SP457]. Nephrology Dialysis Transplantation 2006;21(Suppl 4):iv169. [CENTRAL: CN-00583337]
245. Drueke T, Clyne N, Eckardt K, Locatelli F, Macdougall I, Tsakiris D, et al. Diagnostic value of NT-proBNP and cardiac troponin T in chronic kidney disease patients: correlation with baseline characteristics in the CREATE study [abstract no: P210]. 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15-18; Lisbon, Portugal. 2004:85. [CENTRAL: CN-00509163]
246. Drueke T, Clyne N, Eckardt K, Locatelli F, Macdougall I, Tsakiris D, et al. Homocysteine as a cardiovascular risk marker in patients with chronic kidney disease: baseline data and risk profiles from the CREATE study [abstract no: SP207]. 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15-18; Lisbon, Portugal. 2004:84. [CENTRAL: CN-00509164]
247. Drueke T, Clyne N, Eckardt K, Locatelli F, Macdougall IC, Tsakiris D, et al. Homocysteine as a cardiovascular risk marker in patients with CKD: baseline and 6-month data from the CREATE Study [abstract no: F-PO335]. Journal of the American Society of Nephrology 2004;15(Oct): 139A-40A. [CENTRAL: CN-00550688]
248. Drueke T, Clyne N, Eckardt KU, Locatelli F, Macdougell I, Tsakiris D, et al. Baseline characteristics of chronic renal failure patients not yet receiving renal replacement therapy enrolled in the CREATE study [abstract no: T135]. Nephrology Dialysis Transplantation 2002;17(Suppl 12):227. [CENTRAL: CN-00509165]
249. Drueke T, Locatelli F, Clyne N, Eckardt KU, Macdougall I, Tsakiris D. Cardiovascular disease (CVD) characteristics of chronic kidney disease (CKD) patients enrolled in the 'cardiovascular risk reduction by early anaemia treatment with epoetin beta' (CREATE) study [abstract]. Nephrology Dialysis Transplantation 2003;18(Suppl 4):156. [CENTRAL: CN-00520329]
250. Drueke TB, Clyne N, Eckardt KU, Locatelli F, Macdougall IC, Tsakiris D. Characteristics of chronic kidney disease (CKD) patients enrolled in the 'cardiovascular risk reduction by early anemia treatment with epoetin beta' (CREATE) study [abstract no: SU-P025]. Journal of the American Society of Nephrology 2002;13(September, Program & Abstracts):520A. [CENTRAL: CN-00445149]
251. Drueke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. New England Journal of Medicine 2006;355(20):2071-84. [MEDLINE: 17108342]
252. Eckardt K, Clyne N, Drueke T, Locatelli F, Macdougall I, Tsakiris D, et al. Variables of left ventricular geometry and function in patients enrolled in the CREATE trial [abstract no: T136]. Nephrology Dialysis Transplantation 2002;17 (Suppl 1):227. [CENTRAL: CN-00583726]
253. Eckardt K, Macdougall I, Locatelli F, Tsakiris D, Clyne N, Drueke T. Effects of epoetin beta on left ventricular mass in patients with chronic kidney disease: echocardiographic results from the CREATE study [abstract no: TH-FC172]. Journal of the American Society of Nephrology 2005;16:37A. [CENTRAL: CN-00583370]
254. Eckardt KU, Clyne N, Drueke T, Locatelli F, Macdougall I, Tsakiris D. Left ventricular hypertrophy and associated variables in the 'cardiovascular risk reduction by early anaemia treatment with epoetin beta (CREATE) trial [abstract]. Nephrology Dialysis Transplantation 2003;18 (Suppl 4):155. [CENTRAL: CN-00445194]
255. Eckardt KU, Scherhag A, Macdougall IC, Tsakiris D, Clyne N, Locatelli F, et al. Left ventricular geometry predicts cardiovascular outcomes associated with anemia correction in CKD. Journal of the American Society of Nephrology 2009; 20(12):2651-60. [MEDLINE: 19850955]
256. Eckardt KU, The Cardiovascular risk Reduction by Early Anemia Treatment with Epoetin Beta (CREATE) Trial. The CREATE trial--building the evidence. Nephrology Dialysis Transplantation 2001;16 Suppl 2:16-8. [MEDLINE: 11369844]
257. Locatelli F, Clyne N, Drueke T, Eckardt KU, Macdougall I, Tsakiris D, et al. Distribution of cardiovascular disease (CVD) across three geographical regions in patients with chronic renal failure (CRF) not yet receiving renal replacement therapy (RRT) enrolled in the CREATE study [abstract]. Nephrology Dialysis Transplantation 2002;17 (Suppl 1):227-8. [CENTRAL: CN-00550716]
258. Locatelli F, Del Vecchio L, Pozzoni P. Anemia and cardiovascular risk: the lesson of the CREATE Trial. Journal of the American Society of Nephrology 2006;17(12 Suppl 3): S262-6. [MEDLINE: 17130272]
259. Macdougall IC, Clyne N, Drueke TB, Eckardt K, Tsakiris D, Locatelli F, et al. Left ventricular hypertrophy and related variables in chronic kidney disease patients not receiving RRT enrolled in the cardiovascular risk reduction by early anemia treatment with epoetin beta (CREATE) study [abstract no: SU-PO629]. Journal of the American Society of Nephrology 2003;14(Nov):672A. [CENTRAL: CN-00550747]
260. Macdougall IC, Steering Committee of the CREATE trial, CREATE Study Group. CREATE: new strategies for early anaemia management in renal insufficiency. Nephrology Dialysis Transplantation 2003;18 Suppl 2: ii13-6. [MEDLINE: 12819295]
261. Tsakiris D, Clyne N, Drueke T, Eckardt K, Macdougall I, Locatelli F, et al. Impaired quality of life in chronic kidney disease patients enrolled in the cardiovascular risk reduction by early anemia treatment with epoetin beta (CREATE) study [abstract no: SA-PO723]. Journal of the American Society of Nephrology 2003;14(Nov):456A. [CENTRAL: CN-00550393]
262. Jurkovitz C, Garelnabi M, Rossert J, Frei D,McClellan W. Is there an association between kidney function and oxidative stress? Results from the early correction of anemia on the progression of chronic kidney disease study [abstract no: SU-PO236]. Journal of the American Society of Nephrology 2004;15(Oct):584A. [CENTRAL: CN-00550521]
263. McClellan W, Gassmann-Mayer C, Frei D, Rossert J. Body weight and c-reactive protein interact to accelerate the progression of chronic kidney disease: analysis of the early correction of anemia on the progression of chronic renal insufficiency (ECAP) study [abstract no: SA-PO113]. Journal of the American Society of Nephrology 2004;15(Oct): 325A. [CENTRAL: CN-00550698]
264. Rossert J, Gassmann-Mayer C, Frei D, McClellan W. Prevalence and predictors of epoetin hyporesponsiveness in chronic kidney disease patients. Nephrology Dialysis Transplantation 2007;22(3):794-800. [MEDLINE: 17210593]
265. Rossert J, Gassmann-Mayer C, Frei D, McClellan W. Prevalence and risk factors for erythropoetin hyporesponsiveness in chronic kidney disease: analysis of the ECAP study [abstract no: F-PO343]. Journal of the American Society of Nephrology 2004;15(Oct):141A. [CENTRAL: CN-00550504]
266. Rossert J, Levin A, Roger S, Horl W, Gassman-Mayer C, Frei D, et al. Effect of early correction of anemia on the progression of chronic kidney disease: final results ECAP study [abstract no: SU-PO063]. Journal of the American Society of Nephrology 2004;15(Oct):546A. [CENTRAL: CN-00550517]
267. Rossert J, Levin A, Roger SD, Horl WH, Fouqueray B, Gassmann-Mayer C, et al. Effect of early correction of anemia on the progression of CKD. American Journal of Kidney Diseases 2006;47(5):738-50. [MEDLINE: 16632012]
268. Rossert J, Roger S, Levin A, Horl W, McClellan W. Effect on early correction of anemia on the progression of chronic kidney disease (ECAP) [abstract no: PUB180]. Journal of the American Society of Nephrology 2003;14(Nov):811A. [CENTRAL: CN-00550519]
269. Eschbach JW, Kelly MR, Haley NR, Abels RI, Adamson JW. Treatment of the anemia of progressive renal failure with recombinant human erythropoietin. New England Journal of Medicine 1989;321(3):158-63. [MEDLINE: 2747747]
270. Foley RN, Parfrey PS, Morgan J, Barre P, Campbell P, Cartier P, et al. A randomized controlled trial of complete vs partial correction of anemia in hemodialysis patients with asymptomatic concentric lV hypertrophy or lV dilation [abstract no: A1064]. Journal of the American Society of Nephrology 1998;9(Program & Abstracts):208A. [CENTRAL: CN-00445361]
271. Foley RN, Parfrey PS, Morgan J, Barre P, Campbell P, Cartier P, et al. Diastolic dysfunction in hemodialysis patients: the Canadian Normalization of Hemoglobin Study Group [abstract]. Journal of the American Society of Nephrology 1999;10(Program & Abstracts):261A. [CENTRAL: CN-00550674]
272. Foley RN, Parfrey PS, Morgan J, Barre PE, Campbell P, Cartier P, et al. Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. Kidney International 2000;58(3):1325-35. [MEDLINE: 10972697]
273. Foley RN, Parfrey PS, Morgan J, Barre PE, Campbell P, Cartier P, et al. Hemoglobin levels and hospitalization in hemodialysis patients without symptomatic cardiac disease [abstract no: SA-PO818]. Journal of the American Society of Nephrology 2002;13(September, Program & Abstracts): 432A. [CENTRAL: CN-00445362]
274. Wells GA, Coyne D, Lee KM, Foley RN, Parfrey PS, et al. Quality of life effects of normalization of hemoglobin in asymptomatic hemodialysis patients [abstract]. Journal of the American Society of Nephrology 1998;9(Program & Abstracts):230A. [CENTRAL: CN-00448336]
275. Gouva C, Katapodis K, Siamopoulos K, Investigators of the Study Group. Effect of erythropoietin administration on lipid parameters in chronic renal failure patients. a randomized control trial [abstract no: SP294]. 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15-18; Lisbon, Portugal. 2004:114. [CENTRAL: CN-00509216]
276. Gouva C, Nikolopoulos P, Ioannidis JP, Siamopoulos KC. Treating anemia early in renal failure patients slows the decline of renal function: a randomized controlled trial. Kidney International 2004;66(2):753-60. [MEDLINE: 15253730]
277. Gouva CD, Pappas KD, Katopodis KP, Nikolopoulos PM, Michalis LK, Goudevenos IA, et al. The beneficial effects of erythropoietin on cardiac function and geometry in patients with chronic kidney disease (stage 3 or 4). A randomized control study [abstract no: MP180]. Nephrology Dialysis Transplantation 2005;20(Suppl 5):v260. [CENTRAL: CN-00691682]
278. Papavasiliou EC, Gouva C, Siamopoulos KC, Tselepis AD. Erythrocyte PAF-acetylhydrolase activity in various stages of chronic kidney disease: Effect of long-term therapy with erythropoietin. Kidney International 2005;68(1):246-55. [MEDLINE: 15954914]
279. Papavasiliou EC, Gouva C, Siamopoulos KC, Tselepis AD. PAF-acetylhydrolase activity in plasma of patients with chronic kidney disease. Effect of long-term therapy with erythropoietin. Nephrology Dialysis Transplantation 2006;21 (5):1270-7. [MEDLINE: 16421163]
280. Pappas KD, Gouva CD, Katopodis KP, Nikolopoulos PM, Korantzopoulos PG, Michalis LK, et al. Correction of anemia with erythropoietin in chronic kidney disease (stage 3or 4): effects on cardiac performance. Cardiovascular Drugs & Therapy 2008;22(1):37-44. [MEDLINE: 18095148]
281. Siamopoulos KC, Gouva C, Katopodis KP, Tzallas C, Nikolopoulos P, Papavasiliou EC, et al. Long-term treatment with EPO increases serum levels of high-density lipoprotein in patients with CKD. American Journal of Kidney Diseases 2006;48(2):242-9. [MEDLINE: 16860190]
282. Johnson CA, Wakeen M, Taylor CA 3rd, Zimmerman SW, Burkart J, Bhattacharya A, et al. Comparison of intraperitoneal and subcutaneous epoetin alfa in peritoneal dialysis patients. Peritoneal Dialysis International 1999;19 (6):578-82. [MEDLINE: 10641779]
283. Kawanishi H, Iwasaki M, Akizawa T, Koshikawa S, KRN321 Study Group. Dose-finding and long-term studies of intravenous KRN321 (darbepoetin alfa) in chronic renal failure patients (CRF) on hemodialysis (HD) in Japan [abstract no: SA-PO943]. Journal of the American Society of Nephrology 2005;16:763A. [CENTRAL: CN-00740571]
284. Levin A, Djurdjev O, Thompson C, Barrett B, Ethier J, Carlisle E, et al. Canadian randomized trial of hemoglobin maintenance to prevent or delay left ventricular mass growth in patients with CKD. American Journal of Kidney Diseases 2005;46(5):799-811. [MEDLINE: 16253719]
285. Levin A, Djurdjev O, Thompson CR, Barrett BS. Change in GFR and change in hemoglobin predict change in LVMI [abstract no: SA-PO088]. Journal of the American Society of Nephrology 2004;15(Oct):318A. [CENTRAL: CN-00583328]
286. Levin A, Djurdjev O, Thompson CR, Barrett BS, Euan CJ. Results of the Canadian multicentre randomized control trial (RCT) of erythropoietin therapy for progression anemia in chronic kidney disease [abstract no: SU-PO073]. Journal of the American Society of Nephrology 2004;15(Oct): 548A. [CENTRAL: CN-00583330]
287. Danielson BG, Furuland H, Ahlmen J, Christensson A, Linde T, Strombom U. Scandinavian study of normalizing hemoglobin with rHu-EPO in end stage renal failure [abstract no: A0822]. Journal of the American Society of Nephrology 1999;10(Program & Abstracts):160A. [CENTRAL: CN-00550642]
288. Furuland H, Linde T, Ahlmen J, Christensson A, Strombom U, Danielson BG. A randomized controlled trial of haemoglobin normalization with epoetin alfa in pre-dialysis and dialysis patients. Nephrology Dialysis Transplantation 2003;18(2):353-61. [MEDLINE: 12543892]
289. Furuland H, Linde T, Danielson BG. Cardiac function in patients with end-stage renal disease after normalization of hemoglobin with erythropoietin (EPO) [abstract]. Journal of the American Society of Nephrology 1998;9(Program & Abstracts):337A. [CENTRAL: CN-00445402]
290. Furuland H, Linde T, Danielson BG. Dialysis adequacy after normalization of hemoglobin with erythropoietin (EPO) [abstract]. Journal of the American Society of Nephrology 1998;9(Program & Abstracts):296A. [CENTRAL: CN-00445403]
291. Furuland H, Linde T, Danielson BG. Physical exercise capacity in patients with end-stage renal disease after normalizaton of hemoglobin with erythropoietin (EPO) [abstract]. Journal of the American Society of Nephrology 1998;9(Program & Abstracts):337A. [CENTRAL: CN-00445404]
292. Furuland H, Linde T, Sandhagen B, Andren B, Wikstrom B, Danielson BG. Hemorheological and hemodynamic changes in predialysis patients after normalization of hemoglobin with epoetin-alpha. Scandinavian Journal of Urology & Nephrology 2005;39(5):399-404. [MEDLINE: 16257842]
293. Furuland H, Linde T,Wikstrom B, Danielson BG. Reduced hemodialysis adequacy after hemoglobin normalization with epoetin. Journal of Nephrology 2005;18(1):80-5. [MEDLINE: 15772927]
294. Linde T, Ekberg H, Forslund T, Furuland H, Holdaas H, Nyberg G, et al. The use of pretransplant erythropoietin to normalize hemoglobin levels has no deleterious effects on renal transplantation outcome. Transplantation 2001;71(1): 79-82. [MEDLINE: 11211199]
295. Linde T, Wahlberg J, Furuland H, Danielson BG. Results of renal transplantation in patients randomized to EPO treatment aimed to reach a subnormal or normal Hb [abstract]. Journal of the American Society of Nephrology 1998;9(Program & Abstracts):684A. [CENTRAL: CN-00446408]
296. Locatelli F, Villa G, Messa P, Filippini A, Cannella G, De Ferrari G, et al. Efficacy and safety of once-weekly intravenous epoetin alfa in maintaining hemoglobin levels in hemodialysis patients. Journal of Nephrology 2008;21(3): 412-20. [MEDLINE: 18587731]
297. Kwan JT, Temple M, Macdougall I. Is early treatment of anemia with epoetin-alfa beneficial to predialysis renal patients? An UK multi-centre study [abstract no: SUPO057]. Journal of the American Society of Nephrology 2004; 15(Oct):545A. [CENTRAL: CN-00765503]
298. Macdougall IC, Kwan J, Temple RM, EPO-GBR-2 Investigator Study Group. UK multicentre randomised controlled study of epoetin alfa in early renal insufficiency (ERI)-a 12-month interim analysis [abstract]. Journal of the American Society of Nephrology 2001;12(Program & Abstracts):395A. [CENTRAL: CN-00766947]
299. Macdougall IC, Temple RM, Kwan JT. Is early treatment of anaemia with epoetin-alpha beneficial to pre-dialysis chronic kidney disease patients? Results of a multicentre, open-label, prospective, randomized, comparative group trial. Nephrology Dialysis Transplantation 2007;22(3): 784-93. [MEDLINE: 16968726]
300. Bennett-Jones D. Use of epoetin alpha in the treatment in anaemia in predialysis patients. www.nihr.ac.uk/Profile/ Pages/NRRResults.aspx?publication?id=N0055116759 (last accessed 3 July 2014). [: National Research Register (NRR) Archive, UK]
301. Choukroun G, Kamar N, Lang P, Durrbach A, Lebranchu Y, Adem A, et al. High dose epoetin beta in the first weeks following renal Tx had no influence on renal function in patients at risk for DGF [abstract no: 437]. American Journal of Transplantation 2010;10(Suppl 4):168. [EMBASE: 70463798]
302. Martinez F, Kamar N, Pallet N, Lang P, Durrbach A, Lebranchu Y, et al. High dose epoetin beta in the first weeks following renal transplantation and delayed graft function: Results of the Neo-PDGF Study. American Journal of Transplantation 2010;10(7):1695-700. [MEDLINE: 20642691]
303. Foley RN, Curtis BM, Parfrey PS. Erythropoietin therapy, hemoglobin targets, and quality of life in healthy hemodialysis patients: a randomized trial. Clinical Journal of The American Society of Nephrology: CJASN 2009;4(4): 726-33. [MEDLINE: 19339412]
304. Foley RN, Curtis BM, Parfrey PS. Hemoglobin targets and blood transfusions in hemodialysis patients without symptomatic cardiac disease receiving erythropoietin therapy. Clinical Journal of The American Society of Nephrology: CJASN 2008;3(6):1669-75. [MEDLINE: 18922988]
305. Foley RN, Curtis BM, Parfrey PS. Hemoglobin targets, blood transfusions and quality of life in hemodialysis patients without symptomatic cardiac disease [abstract no: SA-PO2745]. Journal of the American Society of Nephrology 2008;19(Abstracts Issue):730A. [CENTRAL: CN-00756852]
306. Foley RN, Curtis BM, Randell EW, Parfrey PS. Left ventricular hypertrophy in new hemodialysis patients without symptomatic cardiac disease. Clinical Journal of The American Society of Nephrology: CJASN 2010;5(5): 805-13. [MEDLINE: 20378644]
307. Foley RN, Parfrey PS, Wittreich BH, Sullivan DJ, Zagari MJ, Frei D, et al. The effect of higher haemoglobin levels on left ventricular cavity volume in patients starting haemodialysis: a blinded, randomised, controlled trial in. 596 patients without symptomatic cardiac disease [abstract]. 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15-18;Lisbon, Portugal. 2004:217. [CENTRAL: CN-00509197]
308. Parfrey PS, Foley RN, Wittreich BH, Sullivan DJ, Zagari MJ, Frei D. Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. Journal of the American Society of Nephrology 2005;16(7):2180-9. [MEDLINE: 15901766]
309. Parfrey PS, Foley RN, Wittreich BH, Sullivan DJ, Zagari MJ, Frei D, et al. Double-blind comparison of full and partial anemia correction with erythropoietin in incident hemodialysis patients without symptomatic heart disease [abstract no: PUB002]. Journal of the American Society of Nephrology 2004;15(Oct):762A. [CENTRAL: CN-00583759]
310. Parfrey PS, Foley RN, Wittreich BH, Sullivan DJ, Zagari MJ, Frei D, et al. The effect of higher haemoglobin levels on quality of life in patients starting haemodialysis: a blinded, randomised, controlled trial in 596 patients without symptomatic cardiac disease [abstract]. 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15-18; Lisbon, Portugal. 2004:229. [CENTRAL: CN-00509402]
311. Perez-Oliva JF, Casanova-Gonzalez M, Garcia-Garcia I, Porrero-Martin PJ, Valenzuela-Silva CM, Hernandez-Montero T, et al. Comparison of two recombinant erythropoietin formulations in patients with anemia due to end-stage renal disease on hemodialysis: a parallel, randomized, double blind study. BMC Nephrology 2005;6: 5 [MEDLINE: 15910687]
312. Salek M S, Pratheepawanit N. Use of erythropoietin in early anaemia improves health-related quality of life in predialysis chronic renal failure patients [abstract]. Quality of Life Research 2001;10(3):198. [CENTRAL: CN-00495402]
313. Sja'bani M, Asdie AH. Effect of erythropoietin on pruritus and quality of life in chronic hemodialyzed end stage renal disease patients [abstract]. Journal of Clinical Epidemiology 1997;50(Suppl 1):10S. [CENTRAL: CN-00550491]
314. McMahon LP, Roger SD, Levin A, Slimheart Investigators Group. Development, prevention, and potential reversal of left ventricular hypertrophy in chronic kidney disease. Journal of the American Society of Nephrology 2004;15(6): 1640-7. [MEDLINE: 15153576]
315. McMahon LP, Roger SD, Schou M. Does early intervention and treatment with epoetin prevent left ventricular hypertrophy (LVH) in chronic kidney disease (CKD)? (SLIMHEART study) [abstract no: SA-P0852]. Journal of the American Society of Nephrology 2002;13(September, Program & Abstracts):440a. [CENTRAL: CN-00446699]
316. Roger SD, McMahon LP, Clarkson A, Disney A, Harris D, Hawley C, et al. Effects of early and late intervention with epoetin alpha on left ventricular mass among patients with chronic kidney disease (stage 3 or 4): results of a randomized clinical trial. Journal of the American Society of Nephrology 2004;15(1):148-56. [MEDLINE: 14694167]
317. Roger SD, McMahon LP, Schou IM, Aus-14 Investigators Group. Impact of epoetin alfa (EPO) treatment on cardiac and renal function in chronic kidney disease (CKD) [abstract]. Nephrology 2002;7(Suppl 3):70-1. [CENTRAL: CN-00447444]
318. Baldamus C, Krivoshiev S, Wolf-Pflugmann M, Siebert-Weigel M, Koytchev R, Bronn A. Long-term safety and tolerability of epoetin zeta, administered intravenously, for maintenance treatment of renal anemia. Advances in Therapy 2008;25(11):1215-28. [MEDLINE: 18931828]
319. Wizemann V, Rutkowski B, Baldamus C, Scigalla P, Koytchev R, Epoetin Zeta Study Group. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment. Current Medical Research & Opinion 2008;24(3):625-37. [MEDLINE: 18208642]
320. Barany P. Treatment of anemia in hemodialysis (HD) patients (PTS) to a normal hemoglobin concentration (HB)-results of an open randomized clinical trial of epoetin beta [abstract no: M387]. Journal of the American Society of Nephrology 1998;9(Program & Abstracts):243A. [CENTRAL: CN-00444332]
321. Carrera F, Anunciada AI, Nogueira C, Silva JG. Comparison of HB levels in dialysis patients receiving three-times weekly rHuepo switched to once-weekly darbepoetin alfa: results of a randomized study [abstract]. Nephrology Dialysis Transplantation 2003;18(Suppl 4):164. [CENTRAL: CN-00444694]
322. Nissenson A, Nassar G, Edwardes M, Beswick R, Berns J. C.E.R.A. maintains hemoglobin in dialysis patients directly switched from epoetin (EPO) without increasing iron therapy requirements [abstract no: F-PO855]. Journal of the American Society of Nephrology 2007;18(Abstracts): 290A-1A.
323. Ostrvica E, Mesic E, Ostrvica D, Delic J, Delic-Custendil S, Hukic F. Effectiveness of treating the renal anemia in chronic hemodialyzed patients by epoietin alpha and beta. Medicinski Arhiv 2010;64(1):4-6. [MEDLINE: 20422814]
324. Palazzuoli A, Quatrini I, Calabro A, Antonelli G, Caputo M, Campagna MS, et al. Anemia correction by erythropoietin reduces BNP levels, hospitalization rate, and NYHA class in patients with cardio-renal anemia syndrome. Clinical & Experimental Medicine 2011;11(1):43-8. [MEDLINE: 20512394]
325. Besarab A, Canaud B, de Francisco AL, Kerr P, Locatelli F, Lok CE, et al. Randomized comparison of IV C.E.R.A. (Continuous Erythropoietin Receptor Activator) and Darbepoetin Alfa (DA) at extended administration intervals for the maintenance of Hb levels in patients with CKD on dialysis: rationale and design [abstract no: PUB377]. Journal of the American Society of Nephrology 2006;17 (Abstracts):896A. [CENTRAL: CN-00740564]
326. NCT00442702. A randomized, open label study to compare the effect of monthly subcutaneous mircera with that of darbepoetin alfa, given according to local label, on the management of anemia in patients with chronic kidney disease not on dialysis. www.clinicaltrials.gov/show/ NCT00442702 (accessed 8 October 2014).
327. NCT00559273. An open-label, randomized, multicenter, parallel-group study to demonstrate correction of anemia using once every 4 weeks subcutaneous injections of mircera in patients with chronic kidney disease who are not on dialysis. www.clinicaltrials.gov/ct2/show/NCT00559273 (accessed 8 October 2014).
328. NCT00717821. A randomized, controlled, open label, French multicenter parallel group study to compare the hemoglobin maintenance with oncemonthly administration of mircera versus epoetin beta or darbepoetin alfa in patients with chronic kidney disease on hemodialysis. www.clinicaltrials.gov/ct2/show/NCT00717821 (accessed October 2014).
329. NCT00773513. A randomized, open label study to assess all-cause mortality and cardiovascular morbidity in patients with chronic kidney disease on dialysis and those not on renal replacement therapy under treatment with mircera or reference ESAs. www.clinicaltrials.gov/ct2/show/ NCT00773513 (accessed 8 October 2014).
330. Fliser D, Dellanna F, Koch M, Seufert J, Witzke O, Hauser IA. The Primavera study protocol design: evaluating the effect of continuous erythropoiesis receptor activator (C.E.R.A.) on renal function in non-anemic patients with chronic kidney disease. Contemporary Clinical Trials 2011; 32(6):786-92. [MEDLINE: 21762788]
331. NCT00364845. A randomised single-blind study to improve health-related quality of life as measured by the sf-36 vitality score by correcting anemia with aranesp (darbepoetin alfa) in the elderly. www.clinicaltrials.gov/ct2/ show/NCT00364845 (accessed 8 October 2014).
332. Seidenfeld J, Piper M, Bohlius J, Weingart O, Trelle S, Engert A, et al. Comparative effectiveness of epoetin and darbepoetin for managing anemia in patients undergoing cancer treatment. Comparative effectiveness review No.3 (Prepared by Blue Cross and Blue Shield Association Technology Evaluation Center Evidence-based Practice Center under Contract No. 290-02-0026). Rockville, MD: Agency for Healthcare Research and Quality; May 2006. www.effectivehealthcare.ahrq.gov/reports/final.cfm (accessed 8 October 2014).
333. Grant MD, Piper M, Bohlius J, Tonia T, Robert N, Vats V, et al. Epoetin and darbepoetin for managing anemia in patients undergoing cancer treatment: comparative effectiveness update. Comparative Effectiveness Review No. 113. (Prepared by the Blue Cross and Blue Shield Association Technology Evaluation Center Evidence-based Practice Center under Contract No. 290-2007-10058-I). AHRQ Publication No. 13-EHC077-EF. Rockville, MD: Agency for Healthcare Research and Quality. 2013. http: //effectivehealthcare.ahrq.gov/ehc/products/170/1481/ cancer-anemia-treatment-executive-130425.pdf (accessed 8 October 2014).
334. Bohlius J, Schmidlin K, Brillant C, Schwarzer G, Trelle S, Seidenfeld J, et al. Erythropoietin or Darbepoetin for patients with cancer-meta-analysis based on individual patient data. Cochrane Database of Systematic Reviews 2009, Issue 3. [DOI: 10.1002/14651858.CD007303.pub2]
335. Boulware LE, Tangri N, Ephraim PL, Scialla JJ, Sozio SM, Crews DC, et al. Comparative effectiveness studies to improve clinical outcomes in end stage renal disease: the DEcIDE patient outcomes in end stage renal disease study. BMC Nephrology 2012;13:167. [MEDLINE: 23217181]
336. Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in metaanalysis of randomized controlled trials. Journal of Clinical Epidemiology 1997;50(6):683-91. [MEDLINE: 9250266]
337. Caldwell DM, Welton NJ, Ades AE. Mixed treatment comparison analysis provides internally coherent treatment effect estimates based on overviews of reviews and can reveal inconsistency. Journal of Clinical Epidemiology 2010;63(8): 875-82. [MEDLINE: 20080027]
338. Caro JJ, Salas M, Ward A, Goss G. Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer 2001;91 (12):2214-21. [MEDLINE: 11413508]
339. Chaimani A, Higgins JP, Mavridis D, Spyridonos P, Salanti G. Graphical tools for network meta-analysis in STATA. PLoS ONE 2013;8:e76654. [MEDLINE: 24098547]
340. Clement FM, Klarenbach S, Tonelli M, Johnson JA, Manns BJ. The impact of selecting a high hemoglobin target level on health-related quality of life for patients with chronic kidney disease: a systematic review and meta-analysis. Archives of Internal Medicine 2009;169(12):1104-12. [MEDLINE: 19546410]
341. Del Giovane C, Chaimani A, Caldwell D, Salanti G. Exploring the applicability and adaptation of the GRADE system to results from network analysis: a pilot study. 20th Cochrane Colloquium, Auckland, New Zealand. October 2012.
342. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986;7(3):177-88. [MEDLINE: 3802833]
343. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. New England Journal of Medicine 1987;316(2):73-8. [MEDLINE: 3537801]
344. Ezekowitz JA, McAlister FA, Armstrong PW. Anemia is common in heart failure and is associated with poor outcomes: insights from a cohort of 12 065 patients with new-onset heart failure. Circulation 2003;107(2):223-5. [MEDLINE: 12538418]
345. Balshem H, Helfand M, Schunemann HJ, Oxman AD, Kunz R, Brozek J, et al. GRADE guidelines: 3. Rating the quality of evidence. Journal of Clinical Epidemiology 2011; 64(4):401-6. [MEDLINE: 21208779]
346. Groenveld HF, Januzzi JL, Damman K, van Wijngaarden J, Hillege HL, van Veldhuisen DJ, et al. Anemia and mortality in heart failure patients a systematic review and metaanalysis. Journal of the American College of Cardiology 2008; 52(10):818-27. [MEDLINE: 18755344]
347. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327 (7414):557-60. [MEDLINE: 12958120]
348. Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
349. Higgins JP, Jackson D, Barrett JK, Lu G, Ades AE, White IR. Consistency and inconsistency in network metaanalysis: concepts and models for multi-arm studies. Research Synthesis Methods 2012;3(2):98-110. [DOI: 10.1002/jrsm.1044]
350. Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO Clinical practice guideline for anemia in chronic kidney disease. Kidney International Supplements 2010;2(4):279-335. [DOI: 10.1038/ kisup.2012.37]
351. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney International Supplements 2013;3(1): 1-150. [DOI: 10.1038/kisup.2012.73]
352. KDOQI. KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. American Journal of Kidney Diseases 2007;50(3):471-530. [MEDLINE: 17720528]
353. Kilpatrick RD, Critchlow CW, Fishbane S, Besarab A, Stehman-Breen C, Krishnan M, et al. Greater epoetin alfa responsiveness is associated with improved survival in hemodialysis patients. Clinical Journal of The American Society of Nephrology: CJASN 2008;3(4):1077-83. [MEDLINE: 18417744]
354. Lefebvre P, Vekeman F, Sarokhan B, Enny C, Provenzano R, Cremieux PY. Relationship between hemoglobin level and quality of life in anemic patients with chronic kidney disease receiving epoetin alfa. Current Medical Research & Opinion 2006;22(10):1929-37. [MEDLINE: 17022852]
355. Levin NW, Fishbane S, Canedo FV, Zeig S, Nassar GM, Moran JE, et al. Intravenous methoxy polyethylene glycolepoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis: a randomised non-inferiority trial (MAXIMA). Lancet 2007;370(9596): 1415-21. [MEDLINE: 17950856]
356. Locatelli F, Pisoni RL, Combe C, Bommer J, Andreucci VE, Piera L, et al. Anaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrology Dialysis Transplantation 2004; 19(1):121-32. [MEDLINE: 14671047]
357. Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Statistics in Medicine 2004;23(20):3105-24. [MEDLINE: 15449338]
358. Ludwig H, Van Belle S, Barrett-Lee P, Birgegard G, Bokemeyer C, Gascon P, et al. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. European Journal of Cancer 2004;40(15):2293-306. [MEDLINE: 15454256]
359. Macdougall IC, Hutton RD, Cavill I, Coles GA, Williams JD. Treating renal anaemia with recombinant human erythropoietin: practical guidelines and a clinical algorithm. BMJ 1990;300(6725):655-9. [MEDLINE: 2322705]
360. Macdougall IC. An overview of the efficacy and safety of novel erythropoiesis stimulating protein (NESP). Nephrology Dialysis Transplantation 2001;16 Suppl 3: 14-21. [MEDLINE: 11402086]
361. Macdougall IC. Novel erythropoiesis-stimulating agents: a new era in anemia management. Clinical Journal of The American Society of Nephrology: CJASN 2008;3(1):200-7. [MEDLINE: 18077782]
362. Melekhin VV, Shepherd BE, Stinnette SE, Rebeiro PF, Turner MM, Sterling TR. Hemoglobin may contribute to sex differences in mortality among HIV-infected persons in care. PLoS ONE 2012;7(9):e44999. [MEDLINE: 23028732]
363. Neff MS, Goldberg J, Slifkin RF, Eiser AR, Calamia V, Kaplan M, et al. A comparison of androgens for anemia in patients on hemodialysis. New England Journal of Medicine 1981;304(15):871-5. [MEDLINE: 7010161]
364. National Institute for Health and Care Excellence. Anaemia management in people with chronic kidney disease: full guidance. 2011. http://www.nice.org.uk/guidance/CG114/ Guidance (accessed 8 October 2014).
365. Palmer SC, Navaneethan SD, Craig JC, Johnson DW, Tonelli M, Garg AX, et al. Meta-analysis: erythropoiesisstimulating agents in patients with chronic kidney disease. Annals of Internal Medicine 2010;153(1):23-33. [MEDLINE: 20439566]
366. Palmer SC, Saglimbene V, Craig JC, Navaneethan SD, Strippoli GF. Darbepoetin for the anaemia of chronic kidney disease. Cochrane Database of Systematic Reviews 2014, Issue 3 [DOI: 10.1002/14651858.CD009297.pub2]
367. Phrommintikul A,Haas SJ, ElsikM, KrumH.Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a metaanalysis. Lancet 2007;369(9559):381-8. [MEDLINE: 17276778]
368. Salanti G, Higgins JP, Ades AE, Ioannidis JP. Evaluation of networks of randomized trials. StatisticalMethods inMedical Research 2008;17(3):279-301. [MEDLINE: 17925316]
369. Salanti G, Marinho V, Higgins JP. A case study of multipletreatments meta-analysis demonstrates that covariates should be considered. Journal of Clinical Epidemiology 2009;62(8):857-64. [MEDLINE: 19157778]
370. Salanti G, Ades AE, Ioannidis JP. Graphical methods and numerical summaries for presenting results from multipletreatment meta-analysis: an overview and tutorial. Journal of Clinical Epidemiology 2011;64(2):163-71. [MEDLINE: 19157778]
371. Salanti G. Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool. Research Synthesis Methods 2012;3(2):80-97. [DOI: 10.1002/jrsm.1037]
372. Salanti G, Del Giovane C, Chaimani A, Caldwell DM, Higgins JP. Evaluating the quality of evidence from a network meta-analysis. PLoS One 2014;9(7):e99682. [MEDLINE: 24992266]
373. Semba RD, Martin BK, Kempen JH, Thorne JE, Wu AW. The impact of anemia on energy and physical functioning in individuals with AIDS. Archives of Internal Medicine 2005;165(19):2229-36. [MEDLINE: 16246988]
374. Shah S, Smith CJ, Lampe F, Youle M, Johnson MA, Phillips AN, et al. Haemoglobin and albumin as markers of HIV disease progression in the highly active antiretroviral therapy era: relationships with gender. HIV Medicine 2007;8(1): 38-45. [MEDLINE: 17305931]
375. Strippoli GF, Navaneethan SD, Craig JC, Palmer SC. Haemoglobin and haematocrit targets for the anaemia of chronic kidney disease. Cochrane Database of Systematic Reviews 2006, Issue 4. [DOI: 10.1002/ 14651858.CD003967.pub2]
376. Szczech LA, Barnhart HX, Inrig JK, Reddan DN, Sapp S, Califf RM, et al. Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney international 2008;74(6):791-8. [MEDLINE: 18596733]
377. Turner RM, Davey J, Clarke MJ, Thompson SG, Higgins JP. Predicting the extent of heterogeneity in meta-analysis, using empirical data from the Cochrane Database of Systematic Reviews. International Journal of Epidemiology 2012;41(3):818-27. [MEDLINE: 22461129]
378. White IR, Barrett JK, Jackson D, Higgins JP. Consistency and inconsistency in network meta-analysis: model estimation using multivariate meta-regression. Research Synthesis Methods 2012;3(2):111-25. [DOI: 10.1002/ jrsm.1045]
379. de Benoist B, McLean E, Egli I, Cogswell M (editors). Worldwide prevalence of anaemia 1993-2005: WHO global database on anaemia. Geneva: World Health Organization, 2008. [: ISBN: 978 92 4 159665 7]